The Pattern of Malignancies in Karachi (1995 to 1996)

Pages with reference to book, From 157 To 161

Yasmin Bhurgri, A. Rahim, K. Bhutto, P.K. Pinjani (Karachi Cancer Registry; Government of Sindh, Karachi.)

Asif Bhurgri (Department of Pathology, Dow Medical College, Karachi.)

A. Usman (Department of Radiotherapy, Jinnah Postgraduate Medical Centre, Karachi.)

Sheema H. Hasan (Department of Histopathology, Aga Khan University Hospital, Karachi.)

Abstract

Objective: To determine the cancer pattern of the city of Karachi for the years 1995-1996. **Methods:** The Karachi Cancer Registry, established in 1995 by the Government of Sindh, in collaboration with the IARC is an active registry. The staff collect the data pertaining to cancer patients and record it on the registry forms. Hospitals in Karachi, district south as well as some of the hospitals in other districts of the city, where patients are likely to go for treatment or diagnosis are visited. People residing in the district for more than six months prior to the onset of the malignancy were considered residents. All the cases diagnosed on or after 1st January 1995 till 31st December 1996 were considered for analysis.

Results: In the years 1995-96, the most common cancer sites among males were cancers of the lung, oral cavity and lymph nodes. For females, breast cancer ranked first, followed by cancer of the oral cavity and ovary. The age standardized rate for all cancers was 96.3 per 100,000 in males and 96.9 per 100,000 in females. At this early stage of registration we assume that the registry has a missing rate of approximately 20-25%.

Conclusion: The pattern of malignancies in Karachi is similar to the western countries, with lung and breast being the commonest tumors amongst the males and females respectively. The Asian countries have stomach/lung/oral cavity/liver as the commonest tumors amongst the males and cervix/breast amongst the females. Pakistan eing a Muslim country, the incidence of cervical cancer showed an expected low figure JPMA 49:157, 1999).

Introduction

The "Karachi Cancer Registry" is the first population-based cancer registry of Pakistan. Established in January 1995, by the Government of Sindh in collaboration with the International Agency for Research on Cancer (IARC), WHO, this active registry has completed 3 years of data collection.

The registry staff collect cancer data of Karachi District South, from various diagnostic and treatment centres within the district as well as centres outside the district where the cancer cases of District South are likely to go for diagnosis and treatment. The District South of Karachi has the distinction of being the only district in the country with a representation of all ethnic and socioeconomic groups of the country. It can thus be taken as a random sample population of the country in the absence of a nation-wide registration system.

An estimate of the population covered by the cancer registry was prepared for 1995 by IARC, on the basis of the 1981 census. The calculation was based on the assumption that the population structure of Karachi South 2.85 million was similar to the population structure of Pakistan as estimated by the UN for the year 1995. Population of Karachi, District South by localities, projected figures on the basis of the 1981 census was also prepared. The projected figures are based on an annual growth rate of 4,95%¹. This being the average growth-rate for the city of Karachi, as calculated by the Sindh Bureau of Statistics. The census results of 1998 will give the absolute statistical values of our population and the crude incidence rate of the same data may show a variation on subsequent analysis. Incidence is the total number of new cases in a defined time period for a specific population at risk. In the absence of population data, the incidence of a disease cannot be calculated. As such the data of the

Karachi Cancer Registry conies as the first incidence data in the country, as it is a population-based data.

The population-based data of the Karachi Cancer Registry comes after a decade of near complete absence of data from Karachi. Previous to this the Jinnah Postgraduate Medical Centre (JPMC) and the Pakistan Medical and Research Council (PMRC), Cancer Registry was a source of data. The data from JPMC, though a single institution data can be taken as the closest representative of the data of the city of Karachi, as there was only one cancer institute, the Institute of Radiotherapy, JPMC in the city of Karachi till the early eighties.

Materials and Methods

The data of the cancer patients. residents of Karachi-District South was collected from the diagnostic and treatment centres of the district as well as from hospitals outside the district, where the Karachi-District South cancer patients were likely to go for diagnosis and treatment. The registry staff, actively visited these centres either getting computerised data or data from the hospital records. Most of the times the patients were directly interviewed as organised data was not available at most centres. After identification of the cases with a reportable diagnosis, the registry personnel noted the information on identification, referral, investigations and pathology reports, the basis of diagnosis, treatment records and information regarding the patients death.

The completed forms were submitted to the registry office where they were checked and coded. As there were atleast two or more sources of case finding / reporting per case, the forms had to be checked for duplication of the data. A registry number was given to each case. The number of notifications or sources were recorded for each case and the cases were updated as further notifications were received. People residing in the district for more than six months prior to the onset of the malignancy were considered "residents". All the cases diagnosed on or after 1st January 1995 till 3 1st December 1 996 were considered for analysis.

The hospitals within the district, viz the Jinnah Postgraduate Medical Centre, Civil Hospital, Lyari General Hospital, Lady Dufferin Hospital. Sarfaraz Rafiqui Shaheed Hospital, Karachi Adventist Hospital, Anklesaria Hospital and Memon Hospital are the primary sources of data within the district. The bulk of the data is provided by the hospitals of Karachi, located outside District South, viz. Aga Khan University Hospital, Liaquat National Hospital, Baqai Institute of Oncology. Medicare Hospital. The pathology department of the Aga Khan University Hospital, provide diagnostic cover to a large population of Karachi, this includes the residents of Karachi South.

Descriptive epidemiological methods were applied to study cancer incidence for 1995-96. The validity of cancer registration was assessed for both completeness and accuracy. The data of the cancer patients was computerised and analysed using the Canreg-2 computer program, prepared for the registry at the International Agency for Research on Cancer.

The IARC Check program and the Childhood Check program to check data for validity and consistency were used to assess the data. The cases specified by the program as unlikely morphology/site combinations and cases considered unlikely combinations of site and/or histology had already been checked and proved authentic in Karachi.

Results

The age standardized rate for all cancers was 96.3 100,000 in males and 96.9 per 100,000 in females per (Tables 1 and 2).

Table 1:													P 100	000 1	MALE	s					
Age:	Tot.	0-	5-	10-	15-	20-	25-	20.	25.	40-	45.	50-	55-	60-	65-	70-	75+ 6	Crude		S.E. 3.12	ALL SITES
Site	1253	2.6	6.3	7.0	11.1	7.7	13.5	25.1	40.9	101.2	118.5	184.9	229.4	441.9	354.1	490.3	909.5	0.2		0.17	Lip
140:140	5		-		-		-40	+	-		3.4			4.4	4.5		10.7	1.3		0.51	Tongue
141:141	37	+	-	-	-	-	0.5		2.2	6.3	+						10.7	0.5		0.37	Salivary gland
142:142	14	+	-	+	-				0.7			*	3.4	4.0		5.2		0.2		0.16	Qua
143:143	6	+	-	-		0.4			0.7	8.1	5.6 1	3.6 1	11.8 2	24.1 2			32.1	2.5	5.3	0.69	Other mouth
145:145	74	-	-	-		*	0.9	5.1	4.3	1.0	3.0 .	2.7			8.7		10.7	0.6	1.6	0.39	Oropharynx
146:146	19		-	-	0.3	0.4	0.9		1.4		1.1	1.4	3.4	-		5.6	10.7	0.6	1.2	0.34	Nasopharynx
147:147	17	0.2	-		0.3	0.4		0.6	0.7	1.8			3.5 1	15.3 1	11.6		32.1	1.2		0.56	Hypopharynx
148:148	35	-						0.6			-	-		2.2	5.8	10.4	-	0.4		0.25	Pharynx, NOS
149:149	11	-	0.2					0.6	2.9	2.7	4.5	8.2 2	20.2	15 3 2	20.3	8.09	32.1	1.7		0.64	Oesophagus
150:150	51	-				1.1		2.3	2.9		1.1	4.1	7	4.4	8.7	10.4	53.5	1.1		0.58	Stomach
151:151	33	-		10	0.3			0.6	-	-	-	-	1.7	-	2.9		10.7	0.2	0.4		Small intestine
152:152	5		0.2		0.6	0.4	0.5	1.1	2.2	2.7	3.4	5.4	1.7	4.4	5.8	-	10.7	0.9	1.6		Colon
153:153	26		0.2		0.0	0.4	0.9	-	0.7		2.2	5.4	5.1 1	13.1	8.7	5.2		0.8		0.36	Rectum
154:154	25	0.2			-		0.9	0.6	-		4.5	8.2	11.8	17.5	20.3		21.4	1.5	3.6	0.59	Liver
155:155	11	0.2			-		-	-			-	6.8	1.7	-	8.7	5.2	10.7	0.4	1.0	0.33	Gallbladder etc.
156:156				-		-			-	0.9	1.1	1.4	1.7	6.6	2.9		-	0.3	0.6	0.22	Pancreas
157:157	- 3			0.3	-	-	-	-	-	-	1.1	-	-		2.9	-		0.1	0.2	0.11	Peritoneum etc. Nose, sinuses etc.
158:158	3				0.3	-	-		-	1.0			-		-	-	200	0.1	0.1	0.08	
161:161	77			-	0.3	-		2.3	1.4	4.5	4.5	10.9					74.9	2.6	6.7	0.86	Larynx
162:162	155			-	-	-	-	-	2.2	7.2 2	2.4	19.0	32.1	87.5	55.1	88.2 2	160.5		14.3	1.26	Bronchus, lung
	1				-	-		-	0.7		-		*	+			-	0.0	0.0	0.04	Other thoracic org
164:164	47	0.7	0.9	1.0	0.6	1.5	0.5	1.1	1.4	2.7	3.4	5.4	3.4		11.6	10.4	21.4	1.6	2.7	0.49	Haemato./retic. sys
169:169	27	0.2	0.4	1.8	2.2	0.4	0.9			2.7	1.1	1.4	-	2.2		5.2		0.9	1.0	0.22	Bone Connective tissue
171:171	36	0.6	0.2	0.3	0.9	0.4		0.6	-	3.6	5.6	5.4		10.9		15.6	21.4	1.2	2.5	0.49	Skin
173:173	49				0.3		0.5	0.6	0.7	7.2	6.7					10.4	53.5	1.7	4.1	0.24	Male breast
175:175	12	-		-	-	-		0.6	0.7		3.4	1.4	5.1	4.4	2.9			0.4	0.8		Prostate
185:185	34			-	-	-	-	-	4		-	4.1	3.4	21.9		31.1	107.0	1.1	4.2	0.80	Testis
186:186	12	-		-	-		1.4	1.1	2.2	0.9	1.1	1.4	+	-	2.9		-	0.4	0.6	0.18	Other male genital
187:187	3		-	-					0.7		1.1		-		-	5.2		0.1	0.2		Bladder
188:188	79		-				0.5	1.1	0.7	2.7	7.8					57.1	128.4	2.7	7.9	0.31	Kidney
189:189	19	0.2		0.3		0.4			0.7	1.8	2.2	1.4	5.1	6.6		10.4		0.6	0.1	0.09	Eye
190:190	3		0.2		0.3	-		-	-						2.9				2.2	0.40	Brain
191:191	41	-	1.5	0.8	1.5	-	0.9	-	1.4	4.5	10.1	2.7	3.4	4.4	-	5.2	10.7	0.1	0.1	0.07	Other nervous sys.
192:192	4	-		-	0.6		-	0.6	0.7		-		-					0.4	0.8	0.23	Thyroad
	12	-		0.3	-	0.4	0.5	-		0.9	3.4	2.7	-	4.4		5.2	-	0.1	0.1	0.08	Other endocrine
		-		-		-	+	-	-	1.8	-		-			-		0.1	0.2	0.09	Ill defined sites
193:193	2					0.4	4.	0.6	0.7	-			1.7					3.4	5.0	0.56	Lymph nodes
194:194	4		-	-	-	D . T					8.9	9.5		24.1		15.6					
		0.2	2.4	2.1	2.8	1.8	2.3	3.4	3.6	9.9										0.92	Unknown primary
194:194 195:195	4	0.2	2.4	2.1	2.8		2.3	3.4		15.4			21.9	28 4	29.0	26.0	85.6	3.7	8.5	0.92	Unknown primary
194:194 195:195 196:196	100				2.8								21.9	28 4	29.0	26.0	85.6	3.7	8.5	0.92	Unknown primary
194:194 195:195 196:196	100				2.8		1.4	1.1	4.3	15.4	8.9	27.2					85.6	3.7	8.5	0.92	Unknown primary
194:194 195:195 196:196 199:199	100				2.8		1.4	1.1	4.3	15.4	8.9	27.2					85.6	3.7			Unknown primary
194:194 195:195 196:196 199:199 Table 2	100	0.4	0.2	0.3	100	1.8	1.4 INCI	1.1	RATE	15.4 BY AGE	8.9 E GROS	27 2 UP (PE	R 100	,000	FEMO 65-	LES TO-	75+	Crude	ASR	s.x.	
194:194 195:195 196:196 199:199 Table 2	100 109	0.4	5-	0.3	15-	20-	INCID	1.1 DENCE 30-	RATE	15.4 BY AGE	8.9 E GROS	27 2 UP (PE	R 100	,000	PEMP	LES TO-	75+ 682.7	Crude	ASR 96.9	S.E. 3.03	ALL SITES
194 194 195 195 196 196 199 199 Table 2	100 109 Tot.	0.4	0.2	0.3	100	1.8	1.4 INCI	1.1 DENCE	RATE	15.4 BY AGE	8.9 E GROS	27 2 UP (PE	R 100	,000	65- 288.3	LES 70- 411.4	75+	Crude 47.9 0.1	ASR 96.9 0.3	S.E. 3.03 0.24	ALL SITES
194:194 195:195 196:196 199:199 Table 2 Age: Site: 140:140	100 109 Tot. 1313 2	0.4	5-	0.3	15-	20-	INCID	1.1 DENCE 30-	RATE	15.4 BY AGE	8.9 E GROS	27 2 UP (PE	R 100	,000) 60- 354.5 2.3 4.6	65- 288.3	LES 70- 411.4	75+ 682.7	Crude 47.9 0.1 1.2	ASR 96.9 0.3 2.4	S.E. 3.03 0.24 0.43	ALL SITES Lap Tongue
194:194 195:195 196:196 199:199 Table 2: Age Site 140:140 141:141	Tot. 1313 2 33	0.4	5-	0.3	15-	20-	1.4 INCII 25- 27.2	1.1 DENCE 30- 45.3	8ATE 35- 82.9	15.4 BY AGE 40- 172.0 1	8.9 E GROS 45-	27 2 UP (PE 50- 214 1 7 2	SR 100 55 176 0	,000) 60- 354.5 2.3 4.6 2.3	65- 288.3 9.1 3.0	LES 70- 411.4	75+ 682.7	Crude 47.9 0.1 1.2 0.3	ASR 96.9 0.3 2.4 0.5	8.8 3.03 0.24 0.43 0.20	ALL SITES Lip Tongue Salivary gland
194:194 195:195 196:196 199:199 Table 2 Age: Site: 140:140 141:141 142:142	4 100 109 Tot. 1313 2 33 8	0.4	5-	20-7.3	15-	20-	1.4 INCII 25- 27-2 0.5	1.1 DENCE 30- 45.3	4.3 RATE 35- 82.9	15.4 BY AGE 40- 172.0 1	8.9 E GROS 45- 181.0	27 2 UP (PE 50- 214 1 7 2	55- 176 0 8.8	,000) 60- 354.5 2.3 4.6 2.3 2.3	65- 288.3 9.1 3.0	LES 70- 411.4 21.4 5.3	75. 682.7 11.0	Crude 47.9 0.1 1.2 0.3	ASR 96.9 0.3 2.4 0.5	8.8 3.03 0.24 0.43 0.20 0.20	ALL SITES Lip Tongue Salivary gland Gum
194:194 195:195 196:196 199:199 Table 2 Age: Site: 140:140 141:141 142:142 143:143	Tot. 1313 2 33 8 8	0.4	5-	0.3	15-	20-	1.4 INCII 25- 27-2 0.5	1.1 DENCE 30- 45.3	4.3 RATE 35- 82.9	BY AGE 40- 172.0 :	8.9 8 GRO 45- 181.0 3.6 1.2	27 2 UP (PE 50- 214 1 7 2	176 0 8.8	,000) 60- 354.5 2.3 4.6 2.3 2.3 16.0	65- 288.3 9.1 3.0	LES 70- 411.4	75. 682.7 11.0	Crude 47.9 0.1 1.2 0.3 0.3 2.4	ASR 96.9 0.3 2.4 0.5 0.5	8.8 3.03 0.24 0.43 0.20 0.20 0.73	ALL SITES Lip Tongue Salivary gland Gum Other mouth
194:194 195:195 196:196 199:199 Table 2: Age: 5:16 140:140 141:141 142:142 143:143	Tot. 1313 2 33 8 8	0.4	5-	20-7.3	15-	20-15.3	1.4 INCII 25- 27.2 0.5 1.0	1.1 DENCE 30- 45.3 0.6	4.3 PATE 35- 82.9	BY AGE 40- 172.0 : 5.8 1.0	8.9 E GROS 45- 181.0 3.6 1.2 2.4	27 2 UP (PE 50- 214 1 7 2 4 3	8 100 55 176 0 8.8	,000) 60- 354.5 2.3 4.6 2.3 2.3	65- 288.3 9.1 3.0	1LES 70- 411.4 21.4 5.3	75. 682.7 11.0	Crude 47.9 0.1 1.2 0.3 0.3 2.4 0.3	ASR 96.9 0.3 2.4 0.5 0.5 5.3	S.E. 3.03 0.24 0.43 0.20 0.20 0.73 0.29	ALL SITES Lip Tongue Salivary gland Gum Other mouth Oropharyne
194:194 195:195 196:196 196:196 199:199 Table 2: Age: 5:te 140:140 141:141 142:142 143:143 145:145	4 100 109 Tot. 1313 2 33 8 8 65 8	0.4	5-	20-7.3	15-	20-15.3	1.4 INCII 25- 27.2 0.5 1.0	1.1 DENCE 30- 45.3 0.6	4.3 PATE 35- 82.9	BY AGE 40-172.0 1 5.8 1.0 6.8	8.9 8.9 45- 181.0 3.6 1.2 2.4 8.4 1.2	27 2 UP (PE 50- 214 1 7 2 4 3 27.5	SR 100 55- 176 0 8.6 5.3 3.5	.000 1 60- 354.5 2.3 4.6 2.3 2.3 16.0 4.6	9.1 3.0 9.1	1.ES 70- 411.4 21.4 5.3 32.1	75. 682.7 11.0	Crude 47.9 0.1 1.2 0.3 0.3 2.4 0.3 0.2	ASR 96.9 0.3 2.4 0.5 0.5 5.3 0.7	8.E 3.03 0.24 0.43 0.20 0.20 0.73 0.29 0.17	ALL SITES Lip Tongue Salivary gland Gum Other mouth Oropharynx Nasopharynx
194 194 195:195 196:196 199:199 Table 2: Age: 5:100 140:140 141:141 142:142 143:143 145:145 146:146	100 109 Tot. 1313 2 33 8 8 65	0.4	5-	20-7.3	15-	20-15.3	1.4 INCII 25- 27.2 0.5 1.0	1.1 DENCE 30- 45.3 0.6	4.3 PATE 35- 82.9	BY AGE 40- 172.0 : 5.8 1.0	8.9 E GRON 45- 181.0 - 3.6 1.2 2.4 8.4	27 2 UP (PE 50- 214 1 7 2 4 3 27.5	SR 100 55- 176 0 8.8 5.3 3.5 1.8 1.9	,000) 60- 354.5 2.3 4.6 2.3 2.3 16.0	65- 288.3 9.1 3.0	1LES 70- 411.4 21.4 5.3	75+ 692.7 11.0 44.0 11.0	Crude 47.9 0.1 1.2 0.3 0.3 2.4 0.3 0.2	ASR 96.9 0.3 2.4 0.5 0.5 5.3 0.7 0.3	S.E. 3.03 0.24 0.43 0.20 0.20 0.73 0.29 0.17	ALL SITES Lip Tongue Salivary gland Gum Other mouth Orogharyna Nasopharyna Hypopharyna
194 194 195 195 196 196 199 199 Table 2 Age 5:to 100:140 141:141 142:142 143:143 145:145 146:146 147:147 148:148	Tot. 1313 2 33 8 65 8	0.4	5-	20-7.3	15-	20-15.3	1.4 INCII 25- 27.2 0.5 1.0	1.1 DENCE 30- 45.3 1.3 0.6	4.3 PATE 35- 82.9 1.6	BY AGE 40-172.0 : 5.8 1.0 1.0 6.8	8.9 6 GRON 45- 181.0 3.6 1.2 2.4 8.4 1.2	27 2 UP (PE 50- 214 1 7 2 4 3 27.5 1 4	SR 100 55 176 0 8.8 - 5.3 3.5 1.8 1.9	,000) 60- 354.5 2.3 4.6 2.3 2.3 16.0 4.6	9.1 3.0 9.1 -	1LES 70- 411.4 21.4 5.3 32.1 10.7	75+ 692.7 11.0 44.0 11.0	Crude 47.9 0.1 1.2 0.3 0.3 2.4 0.3 0.2 0.5	ASR 96.9 0.3 2.4 0.5 5.5 5.7 0.7 0.3	S.E. 3.03 0.24 0.43 0.20 0.73 0.73 0.17 0.27	ALL SITES Lip Tongue Salivary gland Gum Other mouth Oropharynx Nasopharynx Mypopharynx Mypopharynx Pharynx, NOS
194 194 195 195 196 196 199 199 Table 2: Age: 51te 140 140 141 141 142 147 143 143 145 145 146 146 147 147 148 148	100 109 Tot. 1313 2 33 8 8 65	0.4	5-	20-7.3	15-	20-15.3	1.4 INCII 25- 27.2 0.5 1.0	1.1 DENCE 30- 45.3 1.3 0.6	4.3 RATE 35- 82.9 1.6 - 1.6 - 1.6	BY AGE 40-172.0 1 5.8 1.0 1.0 6.8 -1.0	8.9 6.0 8.9 8.9 8.4 1.2 1.2 6.0	27 2 UP (PE 50- 214 1 - 7 2 4 3 27.5 1.4 - 8.7	55 176 0 8.8 - 5.3 3 5 1.8 1.8 7.0	.000 1 60- 354.5 2.3 4.6 2.3 2.3 16.0 4.6	9.1 3.0 9.1 3.0 9.1	21.4 5.3 32.1 10.7 32.1	75. 692.7 11.0 	Crude 47.9 0.1 1.2 0.3 0.3 2.4 0.3 0.5 0.5	ASR 96.9 0.3 2.4 0.5 0.5 5.3 0.7 0.3	8.E. 3.03 0.24 0.43 0.20 0.73 0.29 0.17 0.27 0.27	ALL SITES Lip Tongue Salivary gland Gum Other mouth Orogharynx Mypopharynx Mypopharynx Pharynx, NOS Cesophagus
194 194 195 195 196 196 199 199 Table 2 Age Site 140 140 141 141 142 142 143 143 146 146 149 149 150 150	Tot. 1313 2 33 8 65 8 53	0.4	5-	20-7.3	15-	1.8 20- 15.3 0.8 0.4 0.4	1.4 INCII 25- 27.2 0.5 1.0 - 1.5 - 1.5	1.1 DENCE 30- 45.3 1.3 0.6	9.35- 82.9 1.6 - 1.6 - 1.6 1.6	BY AGE 40-172.0 1 5.8 1.0 1.0 6.8 -1.0 1.0	8.9 45- 181.0 3.6 1.2 2.4 8.4 1.2 - 1.2 6.0 2.4	27 2 UP (PE 50- 214 1 7 2 4 3 27.5 1.4 - 8.7 4.3	8. 100 55- 176 0 8. 8 5. 3 3. 5 1. 8 1. 8 1. 8	.000 : 60- 354.5 2.3 4.6 2.3 16.0 4.6 - 2.3	9.1 3.0 9.1 3.0 9.1 6.1 30.3 9.1	21.4 5.3 32.1 10.7 10.7 32.1 5.3	75+ 682.7 11.0 44.0 11.0 22.0 22.0 33.0	Crude 47.9 0.1 1.2 0.3 0.3 2.4 0.3 0.2 0.5 0.1 1.9 0.8	ASR 96.9 0.3 2.4 0.5 0.5 5.3 0.7 0.3 0.9 0.9	8.E. 3.03 0.24 0.43 0.20 0.73 0.29 0.17 0.27 0.32	ALL SITES Lip Tongue Salivary gland Gum Other mouth Orogharynx Nasopharynx Hypopharynx Pharynx, NOS Gesophagus Stomach
194:194 195:195 196:196 199:199 Table 2: Age: 5:te 140:140 141:141 142:142 143:143 145:145 146:146 149:149 150:150 151:151	100 109 109 1313 2 33 8 65 8 5 13 3 2 2 2 2 3 3	0.4	5-	20-7.3	15-	20- 15.3 0.8 0.4	1.4 INCII 25- 27.2 0.5 1.0 - 1.5 - 1.5	1.1 DENCE 30- 45.3 0.6 - 1.3 1.3	4.3 PATE 35- 82.9 1.6 - 1.6 - 1.6 1.6 1.6 1.6	BY AGE 40-172.0 : 5.8 1.0 6.8 - 1.0 - 4.9 2.9	8.9 45- 181.0 3.6 1.2 2.4 1.2 - 1.2 6.0 2.4 3.6	27 2 UP (PE 50- 214 1 7 2 4 3 27.5 1 4 8 7 4 3 4 3 4 3 4 3 4 3	8 100 55 176 0 8.8 - 5.3 3.5 1.8 1.8 7.0	,000 (60- 354.5 2.3 4.6 2.3 16.0 4.6 - 2.3	9.1 3.0 9.1 3.0 9.1	1LES 70- 411.4 5.3 32.1 10.7 10.7 32.1 5.3 5.3	75+ 692.7 11.0 44.0 11.0 22.0 22.0 33.0 11.0	Crude 47.9 0.1 1.2 0.3 0.3 2.4 0.3 0.2 0.5 0.1 1.9	ASH 96.9 0.3 2.4 0.5 5.3 0.7 0.3 0.9 0.5 4.2	S.E. 3.03 0.24 0.43 0.20 0.73 0.27 0.32 0.32 0.42	ALL SITES Lip Tongue Salivary gland Gum Other mouth Oropharynx Masopharynx Mypopharynx Mypopharynx Pharynx, MOS Gesophagus Stomach Colon
194 194 195 195 196 196 199 199 Table 2 Age Site 140 140 141 141 142 142 143 143 146 146 147 147 148 148 149 149	Tot. 1313 2 33 8 8 5 5 13 3 52	0.4	5-	20-7.3	15-11.8	1.8 20- 15.3 0.8 0.4 0.4	1.4 INCI: 25- 27-2 0.5 1.0 - 1.5 - 1.5 1.0 0.5	1.1 DENCE 30- 45.3 1.3 0.6	4.3 PATE 35- 82.9 1.6 - 1.6 1.6 1.6 3.1	BY AGE 40-172.0 : 5.8 1.0 6.8 - 1.0 - 4.9 1.9 2.9 2.9 1.0	8 9 8 GRON 45- 181 0 3.6 1.2 2.4 8.4 1.2 6.0 2.4 3.6 1.2	27 2 UF (PE 50- 214 1 7 2 4 3 27.5 1.4 - 8.7 4.3 4.3 4.3 2.9	SR 100 55- 176 0 8.8 	,000 (60- 354.5 2.3 4.6 2.3 2.3 16.0 4.6 2.3 13.7 2.3 6.9	9.1 3.0 9.1 3.0 9.1 3.3 9.1 12.1	1LES 70- 411.4 5.3 32.1 10.7 10.7 10.7 32.1 5.3 5.3	75+ 692 7 11.0 44 0 11.0 22.0 22.0 33.0	Crude 47.9 0.1 1.2 0.3 0.3 2.4 0.3 0.5 0.1 1.9 0.8 1.1	ASR 96.9 0.3 2.4 0.5 0.5 5.3 0.7 0.3 0.9 0.5 4.2 1.6	N.E. 3.03 0.24 0.43 0.20 0.20 0.73 0.29 0.17 0.27 0.27 0.32 0.64 0.48 0.48 0.48 0.48	ALL SITES Lip Tongue Salivary gland Gum Other mouth Orogharynx Nasopharynx Hypopharynx Pharynx, NOS Gesophagus Stomach
194 194 195 195 195 196 196 199 199 199 Table 2: Age Site 140:140 141 142 142 143 144 145 145 145 145 145 145 145 145 145	100 109 Tot. 1313 2 33 8 65 8 5 13 3 3 2 2 2 3 3 2 2 2 2 2 2 2 2 2 2 2	0.4	5-	20-7.3	15-11.8	1.8 20- 15.3 0.8 0.4 0.4 0.4	1.4 INCII 25- 27.2 0.5 1.0 - 1.5 - 1.5	1.1 DENCE 30- 45.3 0.6 - 1.3 1.3	4.3 PATE 35- 82.9 1.6 - 1.6 - 1.6 1.6 1.6 1.6	BY AGE 40-172-0 : 5.8 1.0 6.8 - 1.0 4.9 2.9 1.9 2.9 1.9	8.9 5 GROO 45- 181.0 3.6 1.2 2.4 1.2 6.0 2.4 3.6 1.2 6.0	27 2 UP (PE 50- 214 1 - 7 2 - 4 3 27.5 1.4 - 8.7 4.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2	SR 100 55 176 0 8.8 - 5.3 3.5 1.8 1.8 7.0 1.8 7.0 5.3 3.5	.000 (60- 354.3 2.3 4.6 2.3 2.3 16.0 4.6 - 2.3 13.7	9.1 3.0 9.1 3.0 9.1 3.0 9.1 30.3 9.1 12.1	1LES 70-411.4 5 3 32.1 10.7 10.7 32.1 5.3 5.3 5.3 21.4	75+ 682.7 11.0 44.0 11.0 22.0 33.0 11.0	Crude 47.9 0.1 1.2 0.3 0.3 2.4 0.3 0.2 0.5 0.1 1.9 0.8 1.1	ASR 96.9 0.3 2.4 0.5 5.3 0.7 0.3 0.5 4.2 1.6 1.6	8 E 3.03 0.24 0.43 0.20 0.73 0.29 0.17 0.37 0.32 0.42 0.42 0.42 0.28	ALL SITES Lip Tongue Salivary gland Gum Other mouth Oropharynx Masopharynx Hypopharynx Pharynx, NOS Oesophagus Stomach Colon Rectum Liver
194 194 195 195 196 196 199 199 Table 2 Age Site 140:140 141:141 142:142 143:145 146:146 149:149 150:150 151:151 153:153	Tot. 1313 2 33 8 8 65 5 13 3 52 23 29 15	0.4	5-	20-7.3	15-11.8	1.8 20- 15.3 0.8 0.4 0.4 0.4	1.4 INCI: 25- 27-2 0.5 1.0 - 1.5 - 1.5 1.0 0.5	1.1 DENCE 30- 45.3 0.6 1.3 - 1.3 - 1.3	4.3 PATE 35- 82.9 1.6 - 1.6 1.6 1.6 3.1	BY AGE 40-172.0 1 5.8 1.0 1.0 6.8 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	8.9 6.0 6.0 6.0 6.0 6.0 6.0	27 2 UF (PE 50- 214 1 7 2 4 3 27.5 1.4 - 8.7 4.3 4.3 4.3 2.9	55 176 0 - 8.6 - 5.3 3 5 1.8 1.8 7.0 5.3 3 3.5 7.0	.000 : 60 : 60 : 354.5 : 2.3 : 4.6 : 2.3 : 16.0 : 4.6 : 2.3 : 13.7 : 2.3 : 6.9 : 2.3 : 22.9	9.1 3.0 9.1 3.0 9.1 3.3 9.1 12.1	1LES 70- 411.4 5.3 32.1 10.7 10.7 10.7 32.1 5.3 5.3	75+ 682.7 11.0 44.0 11.0 22.0 33.0 11.0	Crude 47.9 0.1 1.2 0.3 2.4 0.3 0.5 0.1 1.9 0.8 1.1	ASR 96.9 0.3 2.4 0.5 5.3 0.7 0.3 0.5 4.2 1.5 2.0 1.0	S.E. 3.03 0.24 0.43 0.20 0.73 0.29 0.17 0.27 0.32 0.42 0.42 0.48 0.42 0.28	ALL SITES Lip Tongue Salivary gland Gum Other mouth Oropharynx Masopharynx Hypopharynx Hypopharynx Hyarynx, MOS Gesophagus Stomach Colon Rectum Liver Callbladder etc.
194:194 195:195 196:196 199:199 Table 2 Age Site 140:140 141:141 142:142 143:143 146:146 149:149 150:150 151:151 153:153 154:155 156:155	Tot. 1313 33 8 8 55 13 3 522 29 15	0.4	5-	20-7.3	15-11.8	1.8 20- 15.3 0.8 0.4 0.4 0.4 0.4	1.4 INCI: 25- 27-2 0.5 1.0 - 1.5 - 1.5 1.0 0.5	1.1 DENCE 30- 45.3 0.6 - 1.3 1.3	4.3 PATE 35- 82.9 1.6 - 1.6 1.6 1.6 3.1	BY AGE 40-172-0 : 5.8 1.0 6.8 - 1.0 4.9 2.9 1.9 2.9 1.9	8.9 5 GROO 45- 181.0 3.6 1.2 2.4 1.2 6.0 2.4 3.6 1.2 6.0	27 2 UP (PE 50- 214 1 - 7 2 - 4 3 27.5 1.4 - 8.7 4.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2	SR 100 55 176 0 8.8 - 5.3 3.5 1.8 1.8 7.0 1.8 7.0 5.3 3.5	.000 1 60-354.5 2.3 4.6 2.3 16.0 4.6 2.3 13.7 2.3 6.9 2.3 2.3 2.4 6.9	9.1 3.0 9.1 3.0 9.1 3.0 9.1 30.3 9.1 12.1	1LES 70-411.4 5 3 32.1 10.7 10.7 32.1 5.3 5.3 5.3 21.4	75+ 682.7 11.0 44.0 11.0 22.0 33.0 11.0	Crude 47.9 0.1 1.2 0.3 0.3 2.4 0.3 0.2 0.5 0.1 1.9 0.8 1.1	ASR 96.9 0.3 2.4 0.5 0.5 5.3 0.7 0.9 0.5 4.2 1.6 1.6 0.5	S.E. 3.03 0.24 0.43 0.20 0.73 0.27 0.17 0.27 0.32 0.64 0.48 0.48 0.48 0.48 0.48 0.28 0.37 0.30 0.30 0.30	ALL SITES Lip Tongue Salivary gland Gum Other mouth Orogharynx Masogharynx Hypopharynx Pharynx, MOS Gesophagus Stomach Colon Rectum Liver Gallbladder etc. Pancreas
194:194 195:195 196:196 199:199 Table 2: Age	Tot. 1313 2 33 8 6 5 5 13 3 2 2 3 3 2 2 3 3 2 2 3 3 3 2 2 3 3 3 2 2 3 3 2 2 3 2 2 3 2 3 2 3 2 3 2 3 2 3 2 3 2 3 2 3 2 3 3 2 3 3 2 3 2 3 3 2 3 3 2 3 3 3 2 3 3 2 3 3 3 2 3 3 3 3 2 3 3 3 3 2 3	0.4	5-	20-7.3	15-11.8	1.8 20- 15.3 0.8 0.4 0.4 0.4	1.4 TNCII 25- 27.2 0.5 1.0 - 1.5 - 1.5 1.0 0.5 0.5	1.1 DENCE 30- 45.3 0.6 1.3 - 1.3 - 1.3	4.3 PATE 35- 82.9 1.6 - 1.6 1.6 1.6 3.1	BY AGE 40-172.0 1 5.8 1.0 1.0 6.8 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	8.9 6.0 6.0 6.0 6.0 6.0 6.0	27 2 UP (PE 50- 214 1 - 7 2 - 4 3 27.5 1.4 - 8.7 4.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2	55 176 0 - 8.6 - 5.3 3 5 1.8 1.8 7.0 5.3 3 3.5 7.0	,000 1 60- 354.3 2.3 4.6 2.3 2.3 16.0 4.6 - 2.3 13.7 2.3 6.9 2.3 22.9 4.6 6.2 2.3	9.1 3.0 9.1 3.0 9.1 3.0 9.1 30.3 9.1 12.1	1LES 70-411.4 5 3 32.1 10.7 10.7 32.1 5.3 5.3 5.3 21.4	75+ 692.7 11.0 44.0 11.0 22.0 33.0 11.0	Crude 47.9 0.1 1.2 0.3 0.3 0.2 4 0.3 0.2 0.5 0.1 1.9 0.8 1.1 0.5 0.9	ASR 96.9 0.3 2.4 0.5 5.3 0.7 0.3 0.5 4.2 1.5 2.0 1.0	S.E. 3.03 0.24 0.43 0.20 0.20 0.27 0.27 0.27 0.32 0.48 0.48 0.48 0.48 0.48 0.28 0.29 0.20 0.20 0.20 0.20 0.20 0.20 0.20	ALL SITES Lip Tonque Salivary gland Gum Other mouth Oropharynx Nasopharynx Hypopharynx Hypopharynx Stomach Colon Rectum Liver Callbladder etc. Pancreas Peritoreum etc.
194:194 195:195 196:196 199:199 Table 2 Age: 5:to: 140:140 141:141 142:142 143:145 146:146 147:147 148:148 149:149 150:150 151:151 153:153 154:154 155:155 156:156	Tot. 1313 2 33 8 65 8 5 13 3 52 23 29 15 24 37 7	0.4	5-	0.3	15-11.8	1.8 20- 15.3 0.8 0.4 0.4 0.4 0.4	1.4 INCII 25- 27.2 0.5 1.0 1.5 - 1.5 1.0 0.5 0.5	1.1 DENCE 30- 45.3 0.6 1.3 - 1.3 - 1.3	4.3 PATE 35- 82.9 1.6 - 1.6 1.6 1.6 2.3	BY AGI 40- 172 0 1 5.8 1.0 6.8 - 1.0 4.9 1.9 2.9 1.0 1.9	8.9 45-181.0 3.6 1.2 2.4 8.4 1.2 6.0 2.4 3.6 6.0 2.4	27 2 UP (PE 50- 214 1 7 2 4 3 27.5 1.4 - 8.7 4.3 2.9 7.2 4.3	55 176 0 - 8.6 - 5.3 3 5 1.8 1.8 7.0 5.3 3 3.5 7.0	,000) 60- 354.5 2.3 4.6 2.3 16.0 4.6 - 2.3 6.9 2.3 2.3 4.6 9.2 2.3 4.6 9.2 9.2 9.2 9.2 9.2 9.2 9.2 9.2 9.2 9.2	9.1 3.0 9.1 3.0 9.1 12.1 3.0 15.2	1LES 70- 411.4 5.3 32.1 10.7 10.7 32.1 5.3 5.3 5.3 21.4 21.4	75. 692.7 11.0 44.0 11.0 22.0 22.0 33.0	Crude 47.9 0.1 1.2 0.3 0.3 0.2 0.5 0.1 1.9 0.8 1.1 0.9 1.3 0.3	ASH 96.9 0.3 2.4 0.5 5.3 0.7 0.3 0.9 0.5 4.2 1.6 1.6 1.8	8.E 3.03 0.24 0.20 0.20 0.73 0.73 0.29 0.17 0.27 0.32 0.48 0.48 0.42 0.28 0.50 0.50 0.50 0.50	ALL SITES Lip Tongue Salivary gland Gum Other mouth Oropharynx Masopharynx Hypopharynx Pharynx, MOS Cesophagus Stomach Colon Rectum Liver Callbladder etc. Pancreas Peritoneum etc. Nose, sinuses etc.
194 194 195 195 196 199 199 199 199 199 199 141 141 142 142 143 145 145 146 146 147 147 148 148 149 159 159 155 155 156 156 157 158 158	Tot. 1313 2 33 8 8 65 5 13 3 52 23 29 15 24 37 7 3 3	0.4	5-3.0	0.3	15-	20- 15.3 0.8 0.4 0.4 0.4 0.4	1.4 1NC11 25- 27.2 0.5 1.0 1.5 1.5 1.0 0.5 0.5	DENCE 30-45.3 1.3 0.6 1.3 1.3 0.6 0.6	4.3 RATE 35- 82.9 1.6 1.6 1.6 1.6 2.3 0.8	BY AGE 40-172 0 1 1 0 6 8 1 0 0 1 9 2 9 1 0 1 9 5 8 1 0 1 0 1 9 5 8 1 0 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0	8.9 5. GROOM 45- 81.0 3.6 1.2 2.4 4.1 2.4 4.1 2.4 6.0 6.0 6.0 6.0 6.0 6.0 6.0 6.0	27 2 UF (PE 50- 214 1 7 2 4 3 27.5 1 4 8.7 4 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3	SR 1000 55- 176 0 8 8 9 3 3 5 1 8 1 8 1 8 7 0 1 8 7 0 5 3 3 5 7 0 1 8	,000 1 60- 354.5 2.3 4.6 2.3 2.3 16.0 4.6 - 2.3 2.3 2.3 2.3 4.6 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3	9-1 3.0 9-1 3.0 9-1 30.3 9-1 12.1 3.0 15.2	11.65 70-411.4 5.3 32.1 10.7 10.7 32.1 5.3 5.3 5.3 21.4 21.4	75. 692.7 11.0 11.0 11.0 22.0 33.0 11.0	Crude 47.9 0.1 1.2 0.3 0.3 0.2 0.5 0.1 1.9 0.8 1.1 0.5 0.9 1.3 0.1 0.1 0.1	ASH 96.9 9 0.3 2 4 4 2 0.5 5 0.3 0 7 0 3 0 0 5 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	S.E. 3.03 0.24 0.43 0.20 0.73 0.27 0.37 0.37 0.48 0.48 0.48 0.48 0.48 0.48 0.48 0.48	ALL SITES Lip Tongue Salivary gland Gum Other mouth Oropharynx Masopharynx Hypopharynx Hypopharynx Hyarynx, MOS Gesophagus Stomach Colon Rectum Liver Callbladder etc. Pancreas Peritomeum etc. Nose, sinuses etc. Larynx Bronchus, lung
194 194 195 195 196 199 199 199 199 199 141 141 142 142 143 143 145 146 146 149 155 155 155 156 157 158 158 158 158 158 158 158 158 158 158	Tot. 1313 2 33 8 8 65 8 5 13 3 52 23 22 4 3 24 4 3 2 2 4 3 2 2 4 3 2 2 4 3 2 2 4 3 2 2 4 3 2 2 4 3 3 2 2 4 3 3 2 2 4 3 3 2 2 4 3 3 2 2 4 3 3 2 2 4 3 3 2 2 4 3 3 2 2 4 3 3 3 2 2 4 3 3 3 2 2 4 3 3 3 2 2 4 3 3 3 2 2 4 3 3 3 2 2 4 3 3 3 2 2 4 3 3 3 2 2 4 3 3 3 2 2 4 3 3 3 2 2 4 3 3 3 2 2 4 3 3 3 2 2 4 3 3 3 2 2 4 3 3 3 3	0.4	5-	0.3	0.7	20-15.3 0.8 0.4 0.4 0.4	1.4 INCII 25- 27.2 0.5 1.0 1.5 - 1.5 1.0 0.5 0.5	1.1 30-45.3 1.3 0.6 1.3 1.3 0.6 0.6	4.3 PATE 35-82.9 1.6 1.6 1.6 3.1 0.8 2.3	BY AGE 40-172.0 1.72.0 1.00 6.8 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.	8.9 45-81.0 3.6 1.2 2.4 4.1 2.6 0.0 2.4 1.2 2.4 1.2 2.4 1.2 2.4 1.2 2.4 1.2 2.4 1.2 2.4 1.2 2.4 1.2 2.4 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6	27 2 UP (PE 50- 214 1 7 2 4 3 27.5 1 4 - 8.7 4.3 2.9 7.2 4.3 2.9 7.2 4.3 2.9 7.2 4.3 2.9 7.2 4.3 4.3 2.9 4.3 4.3 4.3 4.3 4.3 4.3 4.3 4.3	SR 100 55- 176 0 8.8 - 5.3 3.5 1.8 7.0 5.3 3.5 7.0 1.8 7.0 5.3 3.5 7.0 1.8	,000 ; 60- 354.5 2.3 4.6 2.3 13.7 2.3 6.9 2.3 22.9 4.6 2.3 11.4	9-1 3.0 9-1 3.0 9-1 3.0 9-1 30.3 9-1 12-1 3.0 15-2	LES 70-411.4 21.4 5.3 32.1 10.7 10.7 32.1 1.5 3.3 21.4 21.4 21.4 21.4 21.4 21.4 21.4 21.4	75+ 692 7 11.0 11.0 22.0 22.0 33.0 11.0	Crude 47.9 0.1 1.2 0.3 0.3 0.2 0.5 0.1 1.9 0.8 1.1 0.5 0.3 0.3	ASH, 96.9 96.9 96.9 96.9 96.9 96.9 96.9 96.	8 E 3.03 0.24 0.20 0.20 0.73 0.29 0.27 0.32 0.48 0.48 0.48 0.49 0.50 0.50 0.50 0.13	ALL SITES Lip Tongue Salivary gland Gum Other mouth Oropharynx Masopharynx Mypopharynx Mypopharynx Mypopharynx Mosopharynx Mypopharynx Mypopharynx Mypopharynx Mypopharynx Mypopharynx Mysopharynx Mysopharynx Mysopharynx Stomach Colon Rectum Liver Gallbladder etc. Pancreas Peritoneum etc. Nose, sinuses etc. Larynx Bronchus, lung
194:194 195:195 196:196 199:199 Table 2: Age: 51te 140:140 141:141 142:147 143:143 145:145 146:146 147:147 148:148 150:150 151:151 153:153 154:154 155:155 156:156 157:157 158:158 160:160 161:161 162:162 169:169	Tot. 1309 2 33 8 8 65 5 5 133 299 155 24 37 7	0.4	5-3.0	0.3	15.11.8	20-15.3 0.8 0.4 0.4 0.4 0.4	1.4 INCII 25- 27.2 0.5 1.0 1.5 0.5 0.5 0.5 0.5	1.1 30-45.3 1.3 0.6 1.3 1.3 0.6 0.6	4.3 RATE 35- 82.9 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6	BY AGE 40-172.0 1.0 6.8 1.0 1.9 2.9 1.0 1.9 2.9 1.0 1.9 2.9 1.0 1.9 2.9 1.0 1.9 2.9 1.0 1.9 2.9 1.0 1.9 2.9 1.0 1.9 2.9 1.0 1.9 5.8 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	8.9 45-181.0 3.6 1.2 2.4 1.2 6.0 3.6 6.0 2.4 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2	27 2 UF (PE 50- 214 1 7 2 4 3 27.5 1 4 8.7 4 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3	55 176 0 8 8 8 100 55 176 0 1 8 8 1 8 1 0 0 1 8 1 8 1 8 1 0 0 1 8 1 8	.000 1 60-354.5 2.3 4.6 2.3 16.0 4.6 2.3 13.7 2.3 6.9 2.3 2.3 4.6 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3	9:1 3:0 9:1 3:0 9:1 3:0 6:1 3:0 3:0 3:0 3:0 3:0 3:0 3:0 3:0 3:0 3:0	LES 70-411.4 21.4 3.3 32.1 10.7 32.1 35.3 35.3 21.4 21.4 21.4 21.4 21.4 21.4 21.4 21.4	75. 692.7 11.0 44.0 11.0 22.0 22.0 33.0 11.0	Crude 47.9 0.1 1.2 0.3 0.3 0.3 0.2 0.1 1.9 0.5 0.1 1.0 0.9 0.1 0.1 0.1 0.5 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	AER 96.9 0.3 2.4 4.0 5.3 0.5 5.3 0.9 0.5 2.6 1.1 1.1 1.1 1.1 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2	S.E. 3.03 0.24 0.20 0.20 0.73 0.29 0.17 0.37 0.27 0.32 0.64 0.42 0.42 0.50 0.19 0.10 0.20 0.20 0.20 0.20 0.20 0.20 0.20	ALL SITES Lip Tonque Salivary gland Gum Other mouth Oropharynx Nasopharynx Hypopharynx Hypopharynx Hyarynx, NOS Gesophagus Stomach Colon Rectum Liver Gallbladder etc. Pancreas Peritoreum etc. Nose, sinuses etc. Larynx Bronchus, lung Hiemato / retic.sys Bone
194:194 195:195 196:196 199:199 Table 2: Age: Site: 140:140 141:141 142:142 143:143 145:145 146:146 149:147 148:148 149:149 150:150 151:151 153:153 154:154 155:155 156:156 157:157 158:158 160:160 161:161 162:162 169:169	Tot. 1309 2 33 8 8 5 5 133 29 15 24 37 7 7 3 2 2 11 126 40 15	0.4	5-3.0	0.3	15.00.7	20-15.3 0.8 0.4 0.4 0.4 0.4	1.4 INCII 25- 0.5 1.0 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5	DENCE 30. 45.3 1.3 0.6 1.3 1.3 0.6 0.6 1.9 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3	4.3 PATE 35-82.9 1.6 1.6 1.6 1.6 2.3	BY AGI 40- 172.0 1 5.8 1.0 1.0 6.8 - 1.9 2.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1	8 9 45-181 0 3 6 6 1 2 4 1 2 4 6 0 2 4 6 1 2 6 0 2 4 7 6 0 2 4 7 7 8 7 8 7 8 7 8 7 8 7 8 7 8 7 8 7 8	27 2 50- 214 1 7 2 4 3 7 5 1 4 4 3 4 3 4 3 7 7 2 4 3 2 9 2 9 2 2 9	SR 1000 55- 176 0 8 8 1 8 1 8 1 7 0 0 1 8 7 7 0 0 1 8 1 8 7 1 0 1 8 1 8 7 1 0 1 8 1 8 1 7 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0	13.7 2.3 16.0 2.3 16.0 4.6 6.2 2.3 16.0 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3	9.1 30.3 9.1 3.0 6.1 3.0 3.3 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0	1LES 70-411.4 5 3 32.1 10.7 10.7 5 3 32.1 4 21.4 21.4 21.4 21.4 21.4 21.4 21.4	75. 692.7 11.0 44.0 11.0 22.0 22.0 33.0 11.0	Crude 47.9 0.1 1.2 0.3 0.5 0.5 0.1 1.0 1.5 0.5 0.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	ASR 96.9 0.3 4.2 0.5 0.7 0.7 0.7 0.5 1.2 0.5 0.7 0.7 0.5 1.2 0.5 1.2 0.5 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7	8.E. 3.03 0.24 0.43 0.20 0.73 0.20 0.17 0.27 0.42 0.42 0.28 0.32 0.42 0.29 0.32 0.42 0.29 0.32 0.42 0.20 0.32 0.43 0.20 0.20 0.32 0.32 0.32 0.32 0.32 0.3	ALL SITES Lip Tongue Salivary gland Gum Other mouth Orogharynx Masogharynx Hypogharynx Pharymx, NOS Gesophagus Stomach Colon Rectum Liver Gallbladder etc. Pancreas Peritoneum etc. Nose, sinuses etc. Larynx Bone Gonnective tissue Connective tissue
194 194 195 195 196 199 199 199 199 199 199 140 140 141 141 142 142 143 145 145 146 146 146 147 148 148 149 149 150 150 151 153 154 155 156 157 157 158 158 158 158 158 158 158 158 158 158	4 100 109 109 1313 2 33 8 65 5 13 3 5 5 2 2 3 2 2 3 2 2 3 3 1 1 2 2 2 3 3 3 2 2 2 3 3 3 2 2 3 3 3 3	0.4	0.2	0.3	15. 11.8 0.7 1.0 0.3 1.4 1.4 1.4 1.4	20- 15.3 0.8 0.4 0.4 0.4 0.4 0.4	1.4 INCII 25- 27- 27- 27- 27- 27- 2- 0.5 1.0 0.5 0.5 0.5 0.5 0.5 0.5	1.1 30. 45.3 1.3 0.6 1.3 1.3 0.6 6 1.3 0.6	4.3 PATE 35-82.9 1.66 1.61.61.0.8 2.33 0.88 1.66	BY AGI 40- 172.0 1 5.8 1.0 1.0 6.8 - 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	8 9 9 45 45 45 181 0 3 6 6 12 2 4 4 1 2 2 6 0 6 0 0 2 4 4 1 2 2 2 4 4 2 2 4 4 2 4 4 2 4 4 4 4	27 2 27 2 27 2 27 2 27 2 27 2 27 2 27	8.8 100 55 176 0 8.8 1 8.8 7 7.0 1 1.8 1 7.0 1 1.8 3 7.0 1 1.8 3 7.0 1 1.8 3 7.0 1	10,000 (0,0) (0,000 (0,0) (0,000 (0,0) (0,000 (0,0) (0,000 (0,0) (0,000 (0,0) (0,0) (0,000 (0,0) (0	9:1 30:3 9:1 30:3 9:1 12:1 30:3 30:3 30:3 30:3 30:3 30:3 30:3	1LES 70-411.4 5.3 32.1 10.7 10.7 32.1 5.3 3.2 1.4 21.4 21.4 21.4 21.4 21.4 21.4 21.	75. 682.7 11.0 11.0 22.0 33.0 11.0 22.0 22.0 22.0 66.1	Crude 47.9 1 1.2 2 0.3 3 0.2 2 4 0.5 5 0 0.3 1 0	ASR 96.9 0.3.1 2.4 4.2 5.5 0.5 5.3 7.0 0.9 9.0 1.1 5.2 1.0 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0	S.E. 3.03 0.24 0.43 0.29 0.73 0.29 0.17 0.32 0.42 0.42 0.42 0.42 0.42 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.5	ALL SITES Lip Tongue Salivary gland Gum Other mouth Oropharynx Masopharynx Hypopharynx Hypopharynx Hyarynx, NOS Gesophagus Stomach Colon Rectum Liver Callbladder etc. Pancreas Peritoneum etc. Nose, sinuses etc. Larynx Bronchus, lung Haemato./retic.sys Bone Connective tissue Skin
194 194 195 195 196 199 199 199 199 199 140 140 140 141 141 142 147 149 149 149 150 150 151 153 153 154 155 156 157 157 158 158 160 160 160 160 160 160 160 160 160 160	Tot. 1309 2 33 8 8 5 5 133 29 15 24 37 7 7 3 2 2 11 126 40 15	0.4	0.2	0.3	15- 11.8 0.7 1.0 0.3 1.4 1.4 1.0	20- 15.3 0.8 0.4 0.4 0.4 0.8 0.8 0.8	1.4 INCII 25- 27- 27- 27- 27- 27- 2- 0.5 1.0 0.5 0.5 0.5 0.5 0.5 0.5	1.1 30. 45.3 1.3 0.6 1.3 1.3 0.6 6 1.3 0.6	4.3 PATE 35-82.9 1.66 1.61.61.0.8 2.33 0.88 1.66	BY AGI 40- 172.0 1 5.8 1.0 1.0 6.8 - 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	8 9 9 45 45 45 181 0 3 6 6 12 2 4 4 1 2 2 6 0 6 0 0 2 4 4 1 2 2 2 4 4 2 2 4 4 2 4 4 2 4 4 4 4	27 2 27 2 27 2 27 2 27 2 27 2 27 2 27	8.8 100 55 176 0 8.8 1 8.8 7 7.0 1 1.8 1 7.0 1 1.8 3 7.0 1 1.8 3 7.0 1 1.8 3 7.0 1	10,000 (0,0) (0,000 (0,0) (0,000 (0,0) (0,000 (0,0) (0,000 (0,0) (0,000 (0,0) (0,0) (0,000 (0,0) (0	9:1 30:3 9:1 30:3 9:1 12:1 30:3 30:3 30:3 30:3 30:3 30:3 30:3	1LES 70-411.4 5.3 32.1 10.7 10.7 32.1 5.3 3.2 1.4 21.4 21.4 21.4 21.4 21.4 21.4 21.	75. 682.7 11.0 11.0 22.0 33.0 11.0 22.0 22.0 22.0 66.1	Crude 47.9 1 1.2 2 0.3 3 0.2 2 4 0.5 5 0 0.3 1 0	ASR 96.9 0.3.1 2.4 4.2 5.5 0.5 5.3 7.0 0.9 9.0 1.1 5.2 1.0 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0	S.E. 3.03 0.24 0.43 0.29 0.73 0.29 0.17 0.32 0.42 0.42 0.42 0.42 0.42 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.5	ALL SITES Lip Tongue Salivary gland Gum Other mouth Oropharynx Masopharynx Hypopharynx Hypopharynx Hyarynx, NOS Gesophagus Stomach Colon Rectum Liver Callbladder etc. Pancreas Peritoneum etc. Nose, sinuses etc. Larynx Bronchus, lung Haemato./retic.sys Bone Connective tissue Skin
194 194 195 195 196 199 199 199 199 199 141 141 142 142 143 143 145 146 146 147 149 149 150 150 151 151 153 153 154 154 156 156 157 157 158 158 160 160 160 160 160 160 170 171 171	4 100 109 100 100 100 100 100 100 100 100	0.4	0.2	0.3	15. 11.8 0.7 1.0 0.3 1.4 1.4 1.0	20-15.3 0.8 0.4 0.4 0.4 0.4 0.4 0.6 0.8 0.8 0.8	1.4 INCII 25- 27-2 0.5 1.0 0.5 1.0 0.5 0.5 0.5 0.5 7.2	1.1 30-45.3 1.3 0.6 1.3 1.3 0.6 6 6 1.9 1.3 24.5 24.5	4.3 PATE 35-82.9 1.66 1.66 3.11 0.88 2.3 1.66 0.8 1.66 2.3	BY AGI 40- 5.8 1.0 1.0 6.8 - 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	8 9 9 6 GROV 45	27 2 27 2 27 2 27 2 27 2 27 2 27 2 27	55 176 0 8.8 100 55 1.8 1 8 1 8 1 7 0 0 5 1 8 8 7 0 0 1 8 8 7 0 0 1 8 1 8 1 8 1 1 1 1 1 1 8 1	10,000 1 60- 354.5 2.3 4.6 6 2.3 2.3 16.0 4.6 2.3 7 2.3 22.9 4.6 2.3 22.9 4.6 2.3 3.1 1.4 3.1 1.4 2.3 3.1 1.4 3.1 1.4 2.3 3.1 1.4 3.1 1.4 2.3 3.1 1.4 3.1 1.4 2.3 3.1 1.4 3.1 3.1 1.4 3.1 3.1	9.1 30.3 9.1 12.1 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0	10.7 10.7 10.7 10.7 10.7 10.7 10.7 10.7	75. 692.7 11.0 22.0 22.0 33.0 11.0 22.0 22.0 22.0 11.0 22.0 22.0 22	Crude 47.9 0.3 0.3 0.2 0.5 0.1 1.9 0.1 1.0 0.9 1.3 0.1 0.1 0.9 0.5 0.7 7 0.5 0.7 9	ASH, 96.9 9 0 3 3 4 2 0 5 5 5 5 5 6 7 0 3 3 0 7 5 5 6 7 0 5 5 6 7 0 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6 7 6	S.E. 3.03 0.24 0.43 0.29 0.73 0.29 0.17 0.32 0.42 0.42 0.42 0.42 0.42 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.5	ALL SITES Lip Tonque Salivary gland Gum Other mouth Oropharynx Nasopharynx Hypopharynx Hypopharynx Hynarynx, NOS Gesophagus Stomach Colon Rectum Liver Gallbladder etc. Pancreas Peritoneum etc. Nose, sinuses etc. Larynx Bronchus, lung Hiemato /retic.sys Bone Connective tissue Skin Female breast
194 194 195 195 196 199 199 199 199 199 140 140 140 141 141 142 142 143 145 145 146 146 146 147 147 148 148 148 155 155 156 157 157 158 158 160 160 160 161 162 162 169 169 170 170 171 171 171 173 173	100 100 100 100 100 100 100 100 100 100	0.4	0.2	0.3	15. 11.8 0.7 1.0 0.3 1.4 1.4 1.0	1.8 20- 15.3 0.4 0.4 0.4 0.4 0.8 0.8 0.8 0.8	1.4 INCII 25- 27- 27- 27- 27- 27- 2- 0.5 1.0 0.5 0.5 0.5 0.5 0.5 0.5	1.1 30. 45.3 1.3 0.6 1.3 1.3 0.6 6 1.3 0.6	4.3 PATE 35-9 1.6 1.6 1.6 1.6 2.3 1.6 2.3 44.6	BY AGI 40- 	8 9 9 6 GROV 45	27 2 27 2 27 2 27 2 27 2 27 2 27 2 27	55 176 0 8.8 100 55 1.8 1 8 1 8 1 7 0 0 5 1 8 8 7 0 0 1 8 8 7 0 0 1 8 1 8 1 8 1 1 1 1 1 1 8 1	10,000 1 60- 354.5 2.3 4.6 6 2.3 2.3 16.0 4.6 2.3 7 2.3 22.9 4.6 2.3 22.9 4.6 2.3 3.1 1.4 3.1 1.4 2.3 3.1 1.4 3.1 1.4 2.3 3.1 1.4 3.1 1.4 2.3 3.1 1.4 3.1 1.4 2.3 3.1 1.4 3.1 3.1 1.4 3.1 3.1	9.1 30.3 9.1 12.1 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0	10.7 10.7 10.7 10.7 10.7 10.7 10.7 10.7	75. 692.7 11.0 22.0 22.0 33.0 11.0 22.0 22.0 22.0 11.0 22.0 22.0 22	Crude 47.9 0.3 0.3 0.2 0.5 0.1 1.9 0.1 1.0 0.9 1.3 0.1 0.1 0.9 0.5 0.7 7 0.5 0.7 7	ASH 96.9 96.9 0 5.5 0 7.7 0 5.5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	S.E. 3.03 0.24 0.43 0.20 0.73 0.29 0.17 0.27 0.64 0.42 0.28 0.42 0.28 0.42 0.29 0.13 1.05 0.29 0.13 1.05 0.29 0.13 1.05 0.29 0.13 1.05 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.29	ALL SITES Lip Tongue Salivary gland Gum Other mouth Orogharynx Masopharynx Pharynx, NOS Cesophagus Stomach Colon Rectum Liver Callbladder etc. Pancreas Peritoneum etc. Nose, sinuses etc. Larynx Bronchus, lung Haemato /retic.sys Bone Connective tissue Skin Female breast Uterus
194 194 195 195 196 199 199 199 199 199 199 141 141 142 142 142 143 145 145 146 146 146 146 146 146 146 146 146 146	4 100 109 109 1313 2 33 8 8 65 5 5 13 3 2 2 2 3 3 2 2 3 2 2 3 3 2 2 1 5 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1	0.4	0.2	0.3	15. 11.8 0.7 1.0 0.3 1.4 1.0	20-15.3 0.8 0.4 0.4 0.4 0.4 0.4 0.6 0.6 0.8 0.8 0.8 0.8	1.4 INCIII 25. 27.2 0.5 1.0 0.5 1.0 0.5 0.5 0.5 0.5 0.5 7.2	1.1 30-45.3 1.3 0.6 1.3 1.3 0.6 1.3 0.6 1.3 0.6 1.3 0.6 1.3 0.6 1.3	4.3 RATE 35- 82.9 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6	BY AGI 40-172.0) 5.8 1.0 1.0 6.8 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	8 9 9 6 GROV 45	27.2 50-214.1 7.2 4.3 27.5 1.4 4.3 27.5 1.4 4.3 2.9 2.9 2.9 2.9 2.9 2.9 1.4,5	55 176 0 8.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8	10,000 1 60- 354 5 2 3 4 6 6 2 3 16 0 4 6 6 2 2 3 3 16 2 3 2 3 22 9 4 6 6 2 2 3 3 11 4 2 3 11 4 2 3 11 2 9 9 1 1 1 2 9 1 1 1 1 1 1 1 1 1 1 1	9.1 30.3 9.1 30.3 9.1 12.1 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0	11.ES 70-411.4 5 3 32.1 10.7 10.7 32.1 5 3 3 21.4 421.4 10.7 5 3 3 21.4 421.4 10.7 5 3 3 2 1 10.7 5 3 2 1 10.7 5 2 1	75. 692.7 11.0 22.0 33.0 11.0 22.0 22.0 66.1 11.0	Crude 47.9 1 1.2 2 0.3 3 0.2 2 4 0.5 5 0 0.1 1.9 1.3 0.3 0.3 0.3 1.5 0 0.1 1.5 0 0.7 1.5 9 0.6 8 6 1.7 1.5 9 0.6 8 6 1.7 1.5 9 0.6 8 6 1.7 1.5 9 0.6 8 6 1.7 1.5 9 0.6 8 6 1.7 1.5 9 0.7 1.5 9 0.6 1.7 1.5 9 0.7 1.5 9 0.6 1.7 1.5 9 0.6 1.7 1.5 9 0.7 1.5 9 0.6 1.7 1.5 9 0.7 1.5 9 0.7 1.5 9 0.6 1.7 1.5 9 0.7 1.5 9 0.7 1.5 9 0.7 1.5 9 0.6 1.7 1.5 9 0.7	ASR 96.9 0 3 3 4 4 0 5 5 3 0 7 7 0 5 5 3 3 0 7 7 0 5 5 3 3 0 7 7 0 5 5 5 3 3 0 7 7 1 5 1 5 1 5 1 5 1 5 1 5 1 5 1 5 1 5	8.E. 3.03 0.24 0.43 0.20 0.20 0.27 0.27 0.32 0.64 0.42 0.28 0.29 0.37 0.30 0.30 0.30 0.30 0.30 0.30 0.30	ALL SITES Lip Tongue Salivary gland Gum Other mouth Oropharynx Masopharynx Hypopharynx Hypopharynx Pharynx, NOS Gesophagus Stomach Colon Rectum Liver Callbladder etc. Pancreas Peritoneum etc. Nose, sinuses etc. Larynx Bronchus, lung Haemato./retic.sys Bone Connective tissue Skin Female breast Uterus Cervix uteri
194:194 195:195 196:196 199:199 Table 2: Age: 5:te 140:140 141:141 142:147 148:143 145:145 146:146 149:149 150:150 151:151 153:153 154:154 155:155 156:156 157:157 158:158 160:160 161:161 162:162 169:169 170:170 171:171 173:173 174:174 179:179	4 100 109 109 109 1313 2 33 8 6 5 8 5 5 13 3 2 29 11 24 37 7 7 7 3 2 11 2 2 11 2 12 16 16 16 17 17 18 18 18 18 18 18 18 18 18 18 18 18 18	0.4	0.2	0.3	15. 11.8 0.7 1.0 0.3 1.4 1.4 1.0 0.3	20-15.3 0.8 0.4 0.4 0.4 0.4 0.4 0.8 0.8 0.8 0.8	1.4 INCII 25- 27- 27- 27- 27- 27- 2- 1.5 1.0 0.5 0.5 0.5 0.5 0.5 7.2	1.1 30-45.3 1.3 1.3 1.3 0.6 0.6 0.6 1.9 1.3	4.3 RATE 35-9 1.66 1.	BY AGI 40- 172.0 1 5.8 1.0 1.0 6.8 1.0 1.0 1.9 1.9 1.9 1.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	8 9 9 2 GROW 45-08 10 2 4 4 1 2 2 4 4 1 2 2 4 4 1 2 2 4 6 0 0 2 4 2 2 4 2 4 2 4 2 4 2 4 9 6 0 9 71 2 9 6 6	27 2 27 2 27 2 214 1 7 2 27 5 1 4 4 3 27 5 1 4 4 3 2 9 7 7 2 2 9 2 9 2 9 2 9 2 9 2 9 2 9 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	55. 176.0 8.8 8.8 1.8 7.0 5.3 3.5 7.0 8.3 1.8 7.0 1.8 7.0 1.8 7.0 1.8 7.0 1.8 1.8 7.0 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8	13.7 2.3 4.6 2.3 16.0 2.3 16.0 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3	9:1 3:0 9:1 3:0 9:1 12:1 3:0 3:0 3:0 3:0 3:0 3:0 3:0 3:0 3:0 3:0	10.7 10.7 10.7 10.7 10.7 10.7 10.7 10.7	75. 692.7 11.0 11.0 22.0 33.0 11.0 22.0 22.0 22.0 22.0 66.1.1 242.2 22.0	Crude 47.9 0.1 1.2 2 0.3 3 0.2 2 0.5 0.1 1.9 0.6 0.9 1.3 0.1 0.4 0.5 0.5 0.7 0.1 1.5 0.5 0.7 0.5 0.7 0.7 1.9 0.6 0.3 1.7 0.6 0.7 0.6 0.7 0.7 0.9 0.6 0.7 0.7 0.9 0.6 0.7 0.7 0.9 0.6 0.7 0.7 0.9 0.6 0.7 0.7 0.9 0.6 0.7 0.7 0.9 0.6 0.7 0.7 0.9 0.6 0.7 0.7 0.9 0.6 0.7 0.7 0.9 0.6 0.7 0.7 0.9 0.6 0.7 0.7 0.9 0.6 0.7 0.7 0.9 0.6 0.7 0.7 0.9 0.6 0.7 0.7 0.9 0.6 0.7 0.7 0.9 0.6 0.7 0.7 0.9 0.7 0.7 0.9 0.7 0.7 0.9 0.7 0.7 0.9 0.7 0.7 0.9 0.7 0.7 0.7 0.9 0.7 0.7 0.7 0.9 0.7 0.7 0.7 0.9 0.7 0.7 0.9 0.7 0.7 0.9 0.7 0.7 0.7 0.9 0.7 0.7 0.9 0.7 0.7 0.9 0.7 0.7 0.9 0.7 0.7 0.9 0.7 0.9 0.7 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9	ASR 96.9 96.9 96.9 96.9 96.9 96.9 96.9 96.	S.E. 3.03 0.24 0.43 0.29 0.73 0.29 0.17 0.29 0.17 0.32 0.64 0.42 0.28 0.42 0.19 0.19 0.19 0.19 0.19 0.19 0.19 0.19	ALL SITES Lip Tongue Salivary gland Gum Other mouth Orogharynx Masopharynx Hypopharynx Pharynx, NOS Gesophagus Stomach Colon Rectum Liver Gallbladder etc. Pancreas Peritomeum etc. Nose, sinuses etc. Larynx Bronchus, lung Heemato./retic.sys Bone Connective tissue Skin Female breast Uterus Cervix uteri Placenta
194 194 195 195 196 199 199 199 199 199 140 141 141 142 142 142 143 145 145 146 146 146 146 155 155 156 156 157 157 158 158 158 158 158 158 158 158 158 158	Tot. 1309 1009 1009 1313 2 33 8 8 5 5 13 3 2 29 15 24 37 7 7 3 2 2 11 12 4 4 4 4 4 15 16 16 16 16 17 17 18 18 18 18 18 18 18 18 18 18 18 18 18	0.4	0.2	0.3	15- 11.8 0.7 1.0 0.3 1.4 1.4 1.4 0.3	20- 15.3 0.8 0.4 0.4 0.4 0.6 0.8 0.8 0.8 0.8 0.8 0.8	1.4 INCII 25- 0.5 1.0 0.5 1.0 0.5 1.0 0.5 1.7 0.5 1.0 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0	1.1 30-45.3 1.3 0.6 -1.3 1.3 0.6 -1.3 1.3 0.6 -1.3 0.6 -1.3 0.6 -1.3 0.6 -1.3 0.6 -1.3 0.6 -1.3 0.6 -1.3 0.6 -1.3 0.6 -1.3 0.6 -1.3 0.6 -1.3 0.6 -1.3 0.6 -1.3 0.6 -1.3 0.6 -1.3 0.6 -1.3 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6	4.3 PATE 35- 82.9 1.6 - 1.6 - 1.6 3.1 0.8 0.8 0.8 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6	BY AGI 40- 172.0) 5.8 1.0 0 6.8 - 1.0 1 1.0 1 1.9 1.9 1 1.9 1.9 1 1.9 1	8 9 6 GROOM 45 45 6 6 0 1 2 2 4 4 1 2 2 4 4 1 2 2 4 4 1 2 2 4 4 1 2 2 4 4 7 4 7 1 2 7 4 7 1 2 7 4 7 1 2 7 4 7 1 2 7 4 7 1 2 7 4 7 1 2 7 4 7 1 2 7 4 7 1 2 7 4 7 1 2 7 4 7 1 2 7 4 7 1 2 7 4 7 1 2 7 1	27 2 27 2 27 2 27 2 27 2 27 2 27 2 27	55 176 0 8.8	13.7 2.3 4.6 2.3 4.6 2.3 16.0 4.6 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3	9.1 30.3 9.1 30.3 30.3 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3	1LES 70-411.4 5 32.1 10.7 7 10.7 10.7 5.3 5 10.7 5 10.7 5 10.7 5 10.7 5 10.7 5 10.7 5 10.7 5 10.7 5 10.7 5 10.7 5 10.7 5 10.7 5 10.7 10.7 10.7 10.7 10.7 10.7 10.7 10.7	75. 692.7 11.0 22.0 22.0 11.0 22.0 22.0 22.0 22.0	Crude 47.9 0.3 0.3 0.2 0.5 0.1 1.9 0.1 0.5 0.1 0.1 0.5 0.7 1.3 0.5 0.7 1.5 0.5 0.7 1.5 0.5 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7	ASK 96.9 0	S.R. 3.03 0.24 0.43 0.29 0.29 0.17 0.32 0.29 0.27 0.32 0.29 0.27 0.32 0.29 0.29 0.29 0.29 0.29 0.29 0.29 0.2	ALL SITES Lip Tongue Salivary gland Gum Other mouth Oropharynx Masopharynx Hypopharynx Pharynx, NOS Cesophagus Stomach Colon Rectum Liver Callbladder etc. Pancreas Peritoneum etc. Nose, sinuses etc. Larynx Bronchus, lung Haemato,/retic.sys Bone Connective tissue Skin Female breast Uterus Cervix uteri Placenta Corpus uteri
194:194 195:195 196:196 199:199 Table 2 Age Site 140:140 141:141 142:142 143:143 146:146 149:149 150:150 151:151 153:153 154:154 155:155 156:156 157:157 158:158 160:160 161:161 162:162 169:169 170:170 171:171 173:173 174:174 179:179 180:180	100 100 100 100 100 100 100 100 100 100	0.4	0.2	0.3	15. 11.8 0.7 1.0 0.3 1.4 1.0 0.3	20- 15.3 0.8 0.4 0.4 0.4 0.6 0.8 0.8 0.8 0.8 0.8 0.8	1.4 INCII 25- 27- 27- 27- 27- 27- 2- 1.5 1.0 0.5 0.5 0.5 0.5 0.5 7.2	1.1 30-45.3 1.3 0.6 1.3 1.3 0.6 6 6 1.9 1.3 24.5 24.5	4.3 RATE 35- 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6	BY AGI 40- 172.0 1 5.8 1.0 1.0 6.8 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	8 9 6 GROOT 45-181 0 3 6 6 1 2 2 4 4 1 2 2 4 4 1 2 2 4 6 0 0 2 4 2 4 2 4 2 4 2 4 2 4 2 4 2 4 2 4	27 2 27 2 30 30 30 30 30 30 30 30 30 30 30 30 30 3	55. 176.0 8.8 5.3 3.5 1.8 7.0 1.8 7.0 1.8 7.0 1.8 7.0 1.8 7.0 1.8 1.8 7.0 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8	1000 1 60-60 1	9.1 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0	LES 70-411.4 11.4 11.4 11.4 11.4 11.4 11.4 11.	75. 692.7 11.0 22.0 33.0 11.0 22.0 22.0 22.0 11.0 66.1.1 242.2 242.2 242.2 22.0 22.0 242.2 242.2 242.2 22.0	Crude 47.9 1 1.2 2 0.3 3 0.2 2 4 4 0.5 5 0 0.5 1	ASH 96.9 0 9 0 9 0 9 0 9 0 9 0 9 0 9 0 9 0 9 0	8.E. 3.03 0.24 0.43 0.20 0.20 0.20 0.27 0.32 0.27 0.32 0.48 0.48 0.48 0.48 0.55 0.16 0.17 0.50 0.17 0.17 0.50 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.1	ALL SITES Lip Tonque Salivary gland Gum Other mouth Oropharynx Nasopharynx Hypopharynx Hyarynx, NOS Cesophagus Stomach Colon Rectum Liver Callbladder etc. Pancreas Peritoneum etc. Nose, sinuses etc. Larynx Bronchus, lung Haemato./retic.sys Bone Connective tissue Skin Female breast Uterus Cervix uteri Placenta Corpus uteri Ovary etc.
194:194 195:195 196:196 199:199 Table 2: Age	100 100 100 100 100 100 100 100 100 100	0.4	0.2	0.3	15- 11.8 0.7 1.0 0.3 1.4 1.4 1.4 0.3	20- 15.3 0.8 0.4 0.4 0.4 0.6 0.8 0.8 0.8 0.8 0.8 0.8	1.4 INCII 25- 0.5 1.0 0.5 1.0 0.5 1.0 0.5 1.7 0.5 1.0 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0	1.1 30.4 45.3 1.3 1.3 1.3 0.6 0.6 0.6 1.9 1.3 24.5	4.3 PATE 35-9 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6	BY AGI 40- 	8 9 9 6 9 6 9 6 9 6 9 6 9 6 9 6 9 6 9 6	27 2 27 2 27 2 27 2 27 2 27 2 27 2 27	55 176 0 8.8 8 1 8 1 8 1 8 1 8 1 8 1 8 1 8 1 8 1	10,000 1 60- 354 5 2 3 4 6 6 2 3 2 3 16 0 0 4 6 6 2 3 3 2 3 16 9 9 2 3 2 3 4 6 6 2 3 3 11 4 2 2 3 11 4 2 2 3 1 1 4 2 2 3 2 4 6 6 2 3 2 3 1 1 4 2 2 5 2 4 6 6 2 5 2 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	9.1 30.3 9.1 12.1 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0	LES 70-411.4 5 3 32.1 10.7 7 10.7 26.7 5 3 21.4 6 7 5 3 21.4 6 7 5 3 21.4 6 7 5 3 21.4 6 7 5 5 3 21.4 7 10.7 5 3 2 1 10.7 5 3 2 1 10.7 5 3 2 1 10.7 5	75, 692, 7 11.0 22.0 22.0 22.0 11.0 11.0 22.0 22.0	Crude 47.9 0.3 0.3 2.4 0.5 0.1 1.9 0.5 0.1 1.9 0.9 1.3 0.1 0.9 0.5 0.7 0.7 0.7 0.7 0.7 0.7 0.9 0.3 0.7 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9	ASM 96.93 2.45 0.55 3.00 0.55 3.00 0.50 1.80 2.00 0.50 0.50 0.50 0.50 0.50 0.50 0.5	8.E. 3.03 0.24 0.43 0.20 0.20 0.20 0.27 0.32 0.29 0.17 0.32 0.29 0.17 0.32 0.29 0.17 0.32 0.29 0.17 0.32 0.29 0.17 0.32 0.20 0.20 0.20 0.20 0.30 0.40 0.40 0.40 0.40 0.40 0.40 0.4	ALL SITES Lip Tongue Salivary gland Gum Other mouth Orogharynx Masogharynx Hypogharynx Pharynx, NOS Gesophagus Stomach Colon Rectum Liver Gallbladder etc. Pancreas Peritoneum etc. Nose, sinuses etc. Larynx Bronchus, lung Haemato./retic.sys Bone Connective tissue Skin Female breast Uterus Cervix uteri Placenta Corpus uteri Ovary etc. Oth.female genital
194 194 195 195 196 196 199:199 Table 2 Age Site 140:140 141:141 142:142 143:145 146:146 149:147 149:148 149:150 151:151 151:155 156:156 157:157 188:158 160:160 161:161 162:162 169:169 171:171 173:173 174:174 179:179 180:180	1009 1009 1009 1313 2 33 8 8 65 5 13 3 22 23 22 23 24 37 7 7 7 7 3 2 11 2 4 4 0 15 16 16 16 17 18 18 18 18 18 18 18 18 18 18 18 18 18	0.4	0.2	0.3	15. 11.8 0.7 1.0 0.3 1.4 1.0 0.3	20- 15.3 0.8 0.4 0.4 0.4 0.4 0.8 0.8 0.8 0.8 0.8 1.3	1.4 INCII 25- 0.5 1.0 0.5 1.0 0.5 1.0 0.5 1.7 0.5 1.0 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0	1.1 30-45.3 1.3 0.6 1.3 1.3 0.6 1.3 0.6 1.9 1.3 2.4.5 2.4.5	4.3 PATE 35- 82.9 1.66 1.6	BY AGI 40- 172.0 1 5.8 1.0 1 6.8 - 1.0 1 7.9 1.9 1 1.9	8 9 9 2 GROOM 45 45 12 2 4 4 1 2 2 4 4 7 1 2 2 4 4 1 2 2 4 4 2 4 4 2 4 4 2 4 4 2 4 4 2 4 4 2 4 4 2 4 4 2 4 4 2 4 4 2 4 4 2 4	27.2 50-214.1 7.2 4.3 27.5 1.4 4.3 27.5 1.4 4.3 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9 1.4 4.3 4.3 4.3 4.3 4.3 4.3 4.3 4.3 4.3 4	55 176 0 - 5 3 3 5 3 1 8 8 7 0 0 1 8 7 0 0 1 8	13.77 2.3 16.0 4.6 2.3 16.0 4.6 2.3 13.7 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3	9.1 30.3 9.1 30.3 9.1 12.1 3.0 15.2 57.7 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0	10.77 5.33 10.77 10.77 5.33 10.77 10	75. 692.7 11.0 22.0 33.0 11.0 22.0 22.0 22.0 11.0 22.0 22.0 22	Crude 47.9 0 1.2 2 4 0.5 0.3 0.2 0.5 1.1 0.5 0.5 0.7 1.5 9 0.6 1.7 0.5 9 0.5 1.7 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3	ASH 96.9 0	8.E. 3.03 0.24 0.43 0.20 0.20 0.20 0.27 0.32 0.29 0.17 0.32 0.64 0.43 0.42 0.33 0.55 0.64 0.64 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7	ALL SITES Lip Tongue Salivary gland Gum Other mouth Oropharynx Masopharynx Hypopharynx Hypopharynx Pharynx, NOS Oesophagus Stomach Colon Rectum Liver Callbladder etc. Pancreas Peritoneum etc. Nose, sinuses etc. Larynx Bronchus, lung Hsemato./retic.sys Bone Connective tissue Skin Female breast Uterus Cervix uteri Placenta Corpus uteri Ovary etc. Oth. female genital Bladder
194 194 195 195 196 199 199 199 199 199 140 140 140 141 141 142 147 149 149 150 150 155 156 156 156 157 158 158 159 169 169 170 171 171 173 174 179 180 180 180 180 180 180 180 180 180 180	100 100 100 100 100 100 100 100 100 100	0.4	0.2	0.3	15. 11.8 0.7 1.0 0.3 1.4 1.4 1.4 1.0 0.3	20- 15.3 0.8 0.4 0.4 0.4 0.6 0.8 0.8 0.8 0.8 0.8 0.8	1.4 INCII 25- 27- 27- 27- 27- 27- 2- 0.5 1.0 0.5 0.5 0.5 0.5 0.5 7.2 1.0 1.0	1.1 30.4 45.3 1.3 1.3 1.3 0.6 0.6 0.6 1.9 1.3 24.5	4.3 PATE 35-9 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6	BY AGI 40- 172.0) 5.8 1.0 1.0 6.8 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	8 9 9 6 9 6 9 6 9 6 9 6 9 6 9 6 9 6 9 6	27.2 50-214.1 7.2 4.3 27.5 1.4 4.3 27.5 1.4 4.3 2.9 2.9 2.9 2.9 2.9 2.9 2.9 2.9 1.4 4.3 4.3 4.3 4.3 4.3 4.3 4.3 4.3 4.3 4	55. 176.0 8.8 8.8 1.8 7.0 1.8 7.0 1.8 7.0 1.8 7.0 1.8 1.8 7.0 1.8 1.8 1.8 1.0 1.8 1.8 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	13.7 2.3 3.6 2.3 2.3 3.6 2.3 3.6 2.3 3.6 2.3 3.6 2.3 3.6 2.3 3.6 2.3 3.6 2.3 3.6 2.3 3.6 2.3 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3.6 3	9.1 30.3 9.1 30.3 9.1 12.1 3.0 15.2 57.7 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0	10.77 5.33 10.77 10.77 5.33 10.77 10	75. 692.7 11.0 22.0 22.0 11.0 11.0 22.0 22.0 22.0	Crude 47.9 1 1.2 2 0.3 3 0.3 2.4 4 0.9 1.1 1.9 0.5 0.5 0.1 1.9 0.5 0.9 1.3 3 0.1 1.9 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5	ASM 96.93 2.45 0.55 3.00 0.55 3.00 0.50 0.50 0.50 0.5	S.E. 3.03 0.24 0.43 0.29 0.77 0.29 0.17 0.32 0.64 0.42 0.28 0.42 0.28 0.42 0.29 0.17 0.32 0.42 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.5	ALL SITES Lip Tongue Salavary gland Gum Other mouth Orogharynx Nasopharynx Hypopharynx Pharynx, NOS Oesophagus Stomach Colon Rectum Liver Gallbladder etc. Pancream Peritoreum etc. Nose, sinuses etc. Larynx Bronchus, lung Baemato./retic.sys Bone Connective tissue Skin Female breast Uterus Cervix uteri Placenta Corpus uteri Ovary etc. Oth.female genital Bladder Kidney
194 194 195 195 196 196 199 199 Table 2 Age Situ 140:140 141:141 142:142 143:143 145:145 146:146 147:147 148:148 155:155 156:156 157:157 156:156 157:157 156:156 157:157 157:157 156:156 157:157 157:157 158:158 160:160 161:161 162:162 169:169 170:170 171:171 173:173 174:174 179:179 180:180 181:181 182:182 183:183 184:184 188:188	1009 1009 1009 1313 2 33 8 8 65 5 13 3 22 23 22 23 24 37 7 7 7 7 2 11 26 40 15 16 17 40 40 40 40 40 40 40 40 40 40 40 40 40	0.4	0.5	0.3	15. 11.8 0.7 1.0 0.3 1.4 1.0 0.3	20- 15.3 0.8 0.4 0.4 0.4 0.8 0.8 0.8 3.8	1.4 INCIII 25- 27-2 0.5 1.0 1.5 1.0 0.5 5 0.5 5 7 27 1.1 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	1.1 30-45.3 45.3 1.3 0.6 -1.3 1.3 0.6 0.6 1.9 1.3 24.5 24.5	4.3 PATE 35-9 1.6 1.66 1.66 3.1 0.8 1.6 2.3 44.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1	BY AGG 40- 172.0) 5.8 1.0 1.0 6.8 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	8 9 8 9 8 9 8 9 45 181 0 3 6 6 1.2 2 8 4 1 1 2 2 8 4 1 1 2 2 4 4 2 1 4 2 2 4 4 3 3 6 6 9 1	27 2 27 2 27 2 27 2 27 2 27 2 27 2 27	55 176 0 8.8 1 8.1	10,000 1 60- 354 5 2 3 4 6 6 2 3 2 3 16 0 4 6 6 2 3 2 3 2 3 4 6 6 2 3 3 2 11 4 2 2 3 3 11 4 2 2 3 2 3 4 6 6 9 4 6 4 6 4 6 6	9.1 3.0 9.1 12.1 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0	10.7 10.7 10.7 10.7 10.7 10.7 10.7 10.7	75. 692.7 11.0 22.0 22.0 22.0 11.0 22.0 22.0 22.0	Crude 47.9 0.3 0.3 0.2 0.5 0.1 1.9 0.1 0.5 0.1 0.1 0.5 0.5 0.7 1.3 0.5 0.5 0.7 1.3 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5	ASR 96.90 2.45 0.55 3.00 0.55 3.00 0.55 3.00 0.55 0.55	8.E. 3.03 0.24 0.43 0.20 0.20 0.20 0.27 0.32 0.27 0.32 0.48 0.48 0.48 0.48 0.48 0.48 0.48 0.48	ALL SITES Lip Tongue Salivary gland Gum Other mouth Oropharynx Nasopharynx Pharynx, NOS Gesophagus Stomach Colon Ractum Liver Callbladder etc. Pancreas Peritomeum etc. Nose, sinuses etc. Larynx Beonchus, lung Haemato,/retic.sys Bone Connective tissue Skin Female breast Uterus Cervix uteri Placenta Corpus uteri Ovary etc. Oth. Female genital Bladder Kidney Eye
194 194 195 195 196 196 199 199 Table 2 Age Site 140 141 141 142 142 143 145 146 146 149 149 150 150 151 151 153 153 154 154 155 155 156 156 157 157 158 158 160 160 161 161 162 162 169 169 170 171 173 173 174 174 179 179 180 180 181 181 182 182 184 184 188 188	1009 1009 1009 1009 1001 1001 1001 1001	0.4	0.2	0.3	15. 11.8 0.7 1.0 0.3 1.4 1.0 0.3	20-15.3 0.8 0.4 0.4 0.4 0.4 0.4 0.8 0.8 0.8 0.8 1.3	1.4 INCII 25- 27-2 0.5 1.0 1.5 1.0 0.5 0.5 0.5 7 27 1.0 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0	1.1 30-6 1.3 1.3 0.6 6 1.3 1.3 0.6 6 1.3 24.5 3 3.8 3.8 3.8 3.0 6 6 1.9 1.3 1.3 0.6 6 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9	4.3 RATE 35-9 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6	BY AGI 40- 172.0 1 5.8 1.0 1.0 6.8 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	8 9 9 6 GROOM 45 6 6 9 1 2 2 4 4 1 2 2 4 4 1 2 2 4 6 0 0 2 4 2 4 2 4 2 4 2 4 2 4 2 4 2 4 3 6 6 1 2 4 2 4 4 2 4 4 2 4 4 2 4 4 2	27 2 27 2 30 - 214 1 7 2 4 3 27.5 1.4 	55. 176.0 8.8 5.3 3.5 1.8 7.0 1.8 7.0 1.8 7.0 1.8 7.0 1.8 1.8 7.0 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8	1000 1 60-60 1	9.1 9.1 3.0 9.1 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0	LES 70-411.4 1.4 1.5 3.2 1.1 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7 1.7	75. 692.7 11.0 21.0 21.0 33.0 11.0 22.0 22.0 22.0 22.0 242.2 242.2 22.0 22.0 22.0 22.0 22.0	Crude 47.9 0.1 1.2 2 0.3 0.3 0.2 0.3 0.1 1.9 0.9 1.5 0.5 0.7 1.5 9 0.6 1.7 1.9 0.6 0.7 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8	ASM 96.9 0.3 2.4 5.5 0.7 0.7 0.7 0.5 5.3 0.7 0.7 0.5 5.3 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7	8.R. 3.03 3.03 0.24 0.43 0.20 0.73 0.29 0.77 0.32 0.64 0.43 0.04 0.42 0.37 0.50 0.66 0.42 0.37 0.50 0.66 0.42 0.43 0.43 0.42 0.44 0.44 0.44 0.47 0.66 0.67 0.67 0.67 0.67 0.67 0.67 0.6	ALL SITES Lip Tongue Salivary gland Gum Other mouth Oropharynx Masopharynx Masopharynx Hypopharynx Pharynx, MOS Cesophagus Stomach Colon Rectum Liver Callbladder etc. Pancreas Peritoneum etc. Mose, sinuses etc. Larynx Bronchus, lung Haemato./retic.sys Bone Connective tissue Skin Pemale breast Uterus Cervix uteri Placenta Corpus uteri Ovary etc. Oth.female genital Bladder Kidney Eye Brain
194 194 195 195 196 199 199 199 199 199 199 199 199 199	4 100 109 109 109 1313 2 33 8 65 5 8 5 5 23 29 11 26 40 40 15 15 13 43 47 47 47 47 47 47 47 47 47 47 47 47 47	0.4	0.5	0.3	15- 11.8 0.7 1.0 0.3 1.4 1.4 1.0 0.3 1.0 0.3	1.8 20- 15.3 0.4 0.4 0.4 0.8 0.8 3.8 1.3 3.8	1.4 INCII 25- 0.5 1.0 0.5 1.0 0.5 1.0 0.5 1.7 0.5 1.7 0.5 1.7 0.5 1.7 0.5 1.7 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5	1.1 30.4 45.3 1.3 1.3 1.3 0.6 6.6 1.9 24.5	4.3 PATE 35-9 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6	BY AGI 40- 5.8 4172.0 1 1.0 6.8 49 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9	8 9 9 6 9 6 9 6 9 9 6 9 9 9 9 9 9 9 9 9	27 2 27 2 21 2 30 - 1 2 4 3 7 2 4 3 4 3 4 3 4 3 7 2 9 7 2 9 2 9 2 9 2 9 2 9 2 9 2 9 2 9 1 4 5 5 9 6 9 6 9 7 1 6 9 7 1 7 2 9 1	55. 176.0 8.6 8.6 1.8 7.0 1.8 7.0 1.8 7.0 1.8 7.0 1.8 1.8 1.0 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8 1.8	1,000 1 60-354.5 2.3 4.6 6 2.3 2.3 16.0 0 2.3 7 2.3 16.0 0 2.3 16.0 0 2.3 11.4 2 2.3 13.7 93.8 4.6 6 2.3 13.7 93.8 4.6 6	9.1 30.3 9.1 12.1 30.3 30.3 30.3 30.3 30.3 30.3 30.3 30	LES 70-411.4 5 3 32.1 10.7 7 10.7 32.1 4 21.4 21.4 21.4 21.4 21.4 21.4 21.4	75. 692.7 11.0 21.0 21.0 33.0 11.0 22.0 22.0 22.0 22.0 242.2 242.2 22.0 22.0 22.0 22.0 22.0	Crude 47.9 1 1.2 2 0.3 3 0.2 2 4 0 0.5 5 0.1 1.9 0 0.5 1.3 0 0.1 1.9 0 0.5 1.5 1.9 0 0.6 1.7 0 0.8 0 0.1 0 0.8 0 0.2 0 0.1 0 0.8 0 0.1 0 0.7 0 0.7 0 0.8 0 0.7 0 0.7 0 0.8 0 0.7 0 0.7 0 0.8 0 0.7 0 0	ASR 96.93 2.45 0.55 3.30 0.55 3.30 0.55 3.30 0.55 3.30 0.55 0.55	8.E. 3.03 0.24 0.43 0.20 0.20 0.20 0.27 0.32 0.64 0.43 0.43 0.43 0.42 0.53 0.64 0.42 0.73 0.50 0.73 0.50 0.73 0.50 0.73 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75	ALL SITES Lip Tongue Salivary gland Gum Other mouth Oropharynx Nasopharynx Pharynx, NOS Cesophagus Stomach Colon Rectum Liver Callbladder etc. Pancreas Peritoneum etc. Nose, sinuses etc. Larynx Bronchus, lung Haemato /retic.sys Bone Connective tissue Skin Female breast Uterus Cervix uteri Placenta Corpus uteri Ovary etc. Oth. Tesale genital Bladder Kidney Eye Brain Other NS
194 194 195 195 196 199 199 199 199 199 199 199 199 199	4 100 109 109 109 1313 2 33 8 65 5 8 5 5 23 29 11 26 40 40 15 15 13 43 47 47 47 47 47 47 47 47 47 47 47 47 47	0.4	0.2	0.3	15. 11.8 0.7 1.0 0.3 1.4 1.4 1.0 0.3 3 1.4 1.0 0.3 0.3	1.8 20- 15.3 0.4 0.4 0.4 0.8 0.8 3.8 1.3 3.8	1.4 INCII 25- 0.5 1.0 0.5 1.0 0.5 1.0 0.5 1.7 0.5 1.7 0.5 1.7 0.5 1.7 0.5 1.7 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5	1.1 30.4 45.3 1.3 1.3 1.3 0.6 6.6 1.9 24.5	4.3 PATE 35- 2.9 9 2.9 1.6 6 1.6 6 1.6 6 1.6 6 0.8 1.6 6 1.6 6 0.8 1.6 6 1.6 6 0.8 1.6 6 1.6 6 0.8 1.6 6 1.6 6 0.8 1.6 6 1.6 6 0.8 1.6 6 1.6 6 0.8 1.6 6 1.6 6 0.8 1.6 6 1.6 6 0.8 1.6 6 1.6 6 0.8 1.6 6 1.6 6 0.8 1.6 6 1.6 6 0.8 1.6 6 1.6 6 0.8 1.6 6 1.6 6 0.8 1.6 6 1.6 6 0.8 1.6 6 1.6 6 0.8 1.6 6 1.6 6 0.8 1.6 6 1.6 6 0.8 1.6 6 1.6 6 0.8 1.6 6 1	BY AGG 40- 172.0 1 5.8 1.0 0 6.8 - 1.0 0 1.9 1.9 1 1.9 3.9 4.9 1 1.0 1.9 3 1.9 3.9 4.9 1 1.9 3.9 4.9 1 1.9 3.9 4.9 1 1.9 3.9 3.9 3.9 3.9 3.9 3.9 3.9 3.9 3.9 3	8 9 9 8 9 8 9 8 9 8 9 8 9 8 9 8 9 9 8 9 9 8 9	27 2 50 234 1 7 2 4 3 27 5 1 4 4 3 27 5 1 4 4 3 2 9 7 7 2 2 9 2 9 9 2 9 2 9 2 9 1 4 5 1	55 176 0 - 8.8 1 8 1 8 1 8 1 8 1 8 1 8 1 8 1 8 1 8	1000 1 60-354 5 2 3 4 6 6 2 3 3 11 4 2 3 3 11 4 6 6 2 5 2 2 9 4 6 6 6 6 2 5 2 2 9 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	9.1 30.3 9.1 30.3 9.1 12.1 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0	10.7 10.7 10.7 10.7 10.7 10.7 10.7 10.7	75, 692, 7 11.0 22.0 22.0 33.0 11.0 22.0 22.0 22.0 22.0 22.0 22.0 22	Crude 47.9 0 1 1.2 2 0.3 3 0.2 2 0.5 1 1.9 9 1.3 3 0.1 1 0.5 5 0 0.7 7 1 0.5 9 0.6 6 0.3 3 2 2 0 0.3 3	ASK 96.9 0	S.E. 3.03 0.24 0.43 0.29 0.73 0.77 0.32 0.64 0.42 0.78 0.90 0.17 0.90 0.17 0.90 0.17 0.90 0.17 0.90 0.17 0.90 0.17 0.90 0.17 0.90 0.17 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.9	ALL SITES Lip Tongue Salivary gland Gum Other mouth Oropharynx Masopharynx Hypopharynx Pharynx, NOS Oesophagus Stomach Colon Rectum Liver Callbladder etc. Pancreas Peritoneum etc. Nose, sinuses etc. Larynx Bronchus, lung Haemato,/retic.sys Bone Connective tissue Skin Female breast Uterus Cervix uteri Placenta Corpus uteri Ovary etc. Oth.female genital Bladder Kidney Eye Brain Other NS Thyroid
194 194 195:195 196:196 199:199 Table 2: Age 5:te 140:140 141:141 142:142 143:143 145:145 146:146 149:149 150:150 151:151 153:153 154:154 155:155 156:156 157:157 188:158 160:160 161:161 162:162 169:169 170:170 171:171 173:173 174:174 179:179 180:180 181:181 182:182 183:183 184:188 189:189 199:190 191:191 192:192 199:193	4 100 109 109 1313 2 33 8 65 5 13 3 29 15 24 27 7 7 7 7 7 11 26 40 40 40 40 40 40 40 40 40 40 40 40 40	0.4	0.2 5-3.0 3.0 0.5 0.2 0.2 0.2 0.2 1.1 1.2 0.2	0.3	15. 11.8 0.7 1.0 0.3 1.4 1.0 0.3 1.4 1.0 0.3 2.4 2.4 2.4 2.4 2.4 2.4 2.4 2.4 2.4 2.4	1.8 20- 15.3 0.4 0.4 0.4 0.8 0.8 3.8 1.3 3.8	1.4 INCII 25- 0.5 1.0 0.5 1.0 0.5 1.0 0.5 1.7 0.5 1.7 0.5 1.7 0.5 1.7 0.5 1.7 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5	1.1 30.4 45.3 1.3 1.3 1.3 0.6 6.6 1.9 24.5	4.3 PATE 35-9 1.6 -1.6 -1.6 -1.6 -1.6 -1.6 -1.6 -1.6 -	BY AGI 40- 172.0 1 5.8 1.0 1.0 6.8 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	8 9 9 8 9 8 9 8 9 8 9 8 9 8 9 8 9 8 9 8	27 2 27 2 28 2 21 4 3 3 2 7 4 3 3 4 3 3 2 9 7 7 2 2 9 9 2 9 2 9 2 9 2 9 2 9 2 9 2 9 2 9	100 55 176 0	(,000) 60	911 3003 911 3003 911 3003 911 3003 3003	ALES 70-411.4 11.4 11.4 11.4 11.4 11.4 11.4 11.	75. 692.7 11.0 22.0 22.0 22.0 22.0 22.0 22.0 22.0	Crude 47.9 1 1.2 2 0.3 3 0.3 2 .4 4 0.9 1 1.9 0.5 0.5 0.1 1.9 0.5 0.9 1.3 3 0.1 1.9 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5	ASM 96.93 2.45 0.55 3.00 0.55 3.00 0.50 0.50 0.50 0.5	8.E. 3.03 0.24 0.43 0.20 0.20 0.20 0.27 0.27 0.32 0.27 0.32 0.27 0.32 0.48 0.48 0.48 0.42 0.48 0.48 0.42 0.48 0.48 0.48 0.48 0.48 0.48 0.48 0.48	ALL SITES Lip Tongue Salavary gland Gum Other mouth Orogharynx Nasogharynx Hypogharynx Pharynx, NOS Gesoghagus Stomach Colon Rectum Liver Gallbladder etc. Pancreas Peritoreum etc. Nose, sinuses etc. Larynx Bronchus, lung Baemato./retic.sys Bone Connective tissue Skin Female breast Uterus Corvix uteri Placenta Corpus uteri Ovary etc. Oth female genital Bladder Kidney Eye Brain Other NS Thyroid Other endocrine
194:194 195:195 196:196 199:199 Table 2: Age: 5:te 140:140 141:141 142:147 148:143 145:145 146:146 149:149 150:150 151:151 153:153 154:154 155:155 156:156 161:161 162:162 169:169 170:170 171:171 173:173 174:174 179:179 180:180 181:181 182:182 183:183 184:184 188:188	4 100 109 109 1313 2 33 8 8 65 5 5 23 22 33 29 15 24 37 7 7 7 3 2 11 26 40 15 18 19 19 19 19 19 19 19 19 19 19 19 19 19	0.4	0.2 5-3.0 3.0 0.5 0.2 0.2 0.2 0.2 1.1 1.2 0.2	0.3	155- 11.8 0.7 1.0 0.3 1.4 1.4 1.0 0.3 0.3 0.3 0.3 0.3 0.3 0.3	1.8 20-15.3 0.8 0.4 0.4 0.4 0.8 0.8 3.8 1.3	1.4 INCIII 25- 27-2 0.5 1.0 1.5 1.0 0.5 1.0 0.5 7.2 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	1.1 30-45.3 1.3 0.6 1.3 1.3 1.3 0.6 1.3 0.6 1.3 0.6 1.3 0.6 1.9 0.6 1.9 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6	4.3 PATE 35-82.9 1.66-1.66.1.66.1.66.1.66.1.66.1.66.1.66	BY AGG 40- 172.0 1 5.8 1.0 1.0 1 6.8 - 1.0 1.0 1 1.9 1.9 1 1.9 1.9 1 1.9	8.9 45-181.0 3.6 1.2 2.4 4.1 2.2 4.4 1.2 2.4 4.2 2.4 2.4 2.4 2.4 2.4 3.6 6.0 2.4 1.2 2.4 2.4 2.4 3.6 6.0 2.4 1.2 2.4 3.6 3.6 2.4 1.2 2.4 3.6 3.6 2	27 2 27 2 27 2 27 2 27 2 27 2 27 2 27	55 176 0 8.8 100 5.3 176 0 8.8 1 8 1 8 1 7 0 0 1 8 1 8 1 8 1 7 0 0 1 8 1 8 1 8 1 0 1 0 1 8 1 1 8 1 1 0 1 1 1 1	13.77 2.3 4.6 2.3 16.0 4.6 2.3 13.7 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3	9.1 30.3 9.1 12.1 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0	10.77 5.33 10.77 10.77 5.33 10.77 10.77 5.33 10.77 10.	75. 692.7 11.0 22.0 22.0 11.0 11.0 22.0 22.0 22.0	Crude 47.9 0 47.9 0 . 3 0 . 3 0 . 2 0 . 5 0 . 1 1 . 9 0 . 5 0 . 7 1 . 5 . 9 0 . 6 . 6 0 . 7 1 . 5 . 9 0 . 6 . 6 0 . 7 1 . 9 0 . 6 . 6 0 . 7 1 . 9 0 . 6 . 6 0 . 7 1 . 9 0 . 6 . 6 0 . 7 1 . 9 0 . 6 . 6 0 . 7 1 . 9 0 . 7 1 . 9 0 . 9 0 . 9 0 . 9 0 . 9 0 . 9 0 . 9 0 . 9 0 . 9 0 . 9 0 . 9 0 . 9 0 . 9 0 . 9 0 . 9 0 . 9 0 . 9 0 . 9 0 0 . 9 0 0 0 0	ASK 96.9 0	8.R. 3.03 0.24 0.43 0.20 0.73 0.29 0.77 0.32 0.64 0.43 0.03 0.29 0.78 0.50 0.37 0.50 0.37 0.50 0.37 0.50 0.40 0.40 0.40 0.40 0.40 0.40 0.40	ALL SITES Lip Tongue Salivary gland Gum Other mouth Oropharynx Nasopharynx Pharynx, NOS Gesophagus Stomach Colon Rectum Liver Callbladder etc. Pancreas Peritomeum etc. Nose, sinuses etc. Larynx Beonchus, lung Haemato,/retic.sys Bone Connective tissue Skin Pemale breast Uterus Cervix uteri Placenta Corpus uteri Ovary etc. Oth. Female genital Bladder Kidney Eye Brain Other NS Thyroid Other endocrine Ill defined sites
194:194 195:195 199:199 Table 2** Age Site 140:140 141:141 142:142 143:145 146:146 147:147 148:148 149:149 150:150 151:151 153:153 154:154 155:155 156:156 157:157 158:158 160:160 161:161 162:162 169:169 170:170 171:171 173:173 174:174 179:179 180:180 181:181 182:182 183:183 184:184 188:188 189:189 190:190 191:191 192:192 193:193 194:194	4 100 100 100 100 100 100 100 100 100 10	0.4	0.2	0.3	150 11.8 0.7 1.0 0.3 1.4 1.4 1.0 0.3 0.3 2.4	1.8 20- 15.3 0.8 0.4 0.4 0.4 0.8 0.8 3.0 1.3	1.4 INCII 25- 27-2 0.5 1.0 0.5 1.0 0.5 0.5 0.5 7.2 1.0 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0	1.1 30.4 45.3 1.3 1.3 1.3 0.6 6.6 1.9 24.5	4.3 PATE 35-9 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6	BY AGI 40- 172.0 1 5.8 1.0 1.0 6.8 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	8 9 9 8 9 8 9 8 9 8 9 8 9 8 9 8 9 8 9 9 8 9	27 2 27 2 28 2 21 4 3 2 2 2 4 3 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3 4 3 4	100 55 176 0 8.8 8 1 8 1 1 8 1 7 0 0 1 8 1 8 1 8 1 7 0 0 1 8 1 8 1 8 1 8 1 8 1 8 1 8 1 8 1 8	1,000 1 60-354.5 2.3 4.6 2.3 2.3 16.00 2.3 2.3 2.3 16.00 2.3 2.3 22.9 2.3 22.9 2.3 22.9 2.3 22.9 2.3 22.9 2.3 22.9 2.3 22.9 2.3 22.9 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3	9:1 3.0 9:1 3.0 9:1 12:1 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0	LES 70-411.4 11.4 11.4 11.4 11.4 11.4 11.4 11.	75. 692.7 11.0 22.0 22.0 22.0 22.0 22.0 22.0 22.0	Crude 47.9 0.1 1.2 2 0.3 3 0.3 2.4 4 0.9 1.1 1.9 0.5 0.9 1.3 3 0.1 1.5 0.5 0.7 0.1 1.5 9 0.6 3.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0	ASM 96.93 2.45 0.55 3.0 0.55 3.0 0.5 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1	8.E. 3.03 0.24 0.43 0.20 0.20 0.20 0.17 0.27 0.32 0.27 0.32 0.27 0.32 0.48 0.48 0.48 0.48 0.48 0.48 0.48 0.48	ALL SITES Lip Tongue Salivary gland Gum Other mouth Oropharynx Nasopharynx Hypopharynx Pharynx, NOS Oesophagus Stomach Colon Rectum Liver Callbladder etc. Pancreas Peritoneum etc. Nose, sinuses etc. Larynx Bronchus, lung Haemato./retic.sys Bone Connective tissue Skin Female breast Uterus Cervix uteri Placenta Corpus uteri Ovary etc. Oth female genital Bidder Kidney Eye Brain Other NS Thyroid Other endocrine Ill defined sites Lymp nodes

The leading malignancy in the males was the cancer of the lung with 155 (12.4%) incident cases for the years 1995 and 1996. The histological type was predominantly squamous cell carcinoma. Associated with cigarette smoking, this malignancy was seen predominantly in the males. The number of the female lung cases was low. The peak incidence was in the seventh decade of life. 129 (80%) cases were seen between the sixth to eighth decade.

The second most common malignancy amongst the males was carcinoma of the oral cavity, with 1 36 (10.9%) cases for the years 1 995 and 1996. Oral cancer is known to be associated with tobacco

smoking and areca, tobacco and betal-quid chewing. This would explain the high incidence rate in both the males and the females. Carcinoma of the oral cavity showed a plateau between the fourth and eighth decade with a peak incidence in the seventh decade.

Table 3. Age Adjusted Rates* of Cancer.

Registry	AAR*	AAR*
	Males	Females
Karachi, Pakistan	96.3	96.9
Madras, India	104.2	129.0
Shanghai, China	246.9	169.1
Songkhla, Thailand	116.7	88.7
Seoul, Korea	232.4	147.9
Spain	238.0	179.0
Netherland	443.0	309.0

The third most common malignancy was of the lymph nodes, with 100(8.0%) cases for the years 1995 and 1996. Lymphomas, both the Hodgkin's and the Non-Hodgkin's variety, with an even distribution in all the age groups were seen. The lymphomas and the leukemias form the bulk of the tumours in the first two decades of life. The age standardized rates for cancers of lung, oral cavity and lymph nodes in the males were 14.3. 9.0 and 5.0 per 100,000 respectively.

The most common malignancy in the females was carcinoma of the breast, with 436 (33.2%) incident cases for the years 1995 and 1996. The age pattern was typical of that observed in the developing countries with an increase in the risk around the fourth decade, peak at the age of around 45 years, i.e. perimenopausal, followed by an apparent slight decrease in the risk.

The second and the third most common malignancies amongst the females were of the oral cavity and the ovary. Carcinoma of the oral cavity with 116 (8.9%) cases for the years 1995 and 1996, and carcinoma of the ovary with 88 (6.7%) cases were seen for the same period. The malignancies of the oral cavity were seen predominantly in females above the age of 40 years, though the malignancies of the oral cavity were also observed in the second and third decades of life. The age standardized rates for cancers of breast, oral cavity and ovary in the females were 31.5, 8.5 and 6.0 per 100,000 respectively.

Validity and completeness are the essential components in assessing the quality of cancer registry data. The indicator of validity used are cases with histological verification (H.V.), and cases registered on the basis of information only from a death certificate (D.C.O.). The percentage of cases which were verified histologically for the year 1995 was 89.9%, for 1996 it was 88.7%. These included cases which were diagnosed on the basis of tissue or needle biopsy either of the primary or the secondary site of the tumour. Including the cases diagnosed on the basis of cytology or haematology this percentage rose to 94.0% for 1995 and 93.9% for 1996. The high HV% is an indicator that Karachi has diagnostic facilities at par with international standards.

Discussion

There is no incidence data available to date in Pakistan. The data on cancer occurrence in Karachi (1978-83) published by IARC, based on the studies by the PMRC and JMPC put pharynx and lung as the most common cancer sites amongst the males and breast amongst the females². This indicates a slight change of trend in malignancy in the two genders.

The population-based data of the Karachi Cancer Registry shows a slightly different pattern from the data of Karachi analysed from JPMC. There has been an overall increase in the total number of malignancies. The JPMC data showed an average of 2070 new cases annually, for the city of Karachi. The Karachi Cancer Registry data shows an average of 1270 new cases of cancer annually (both sexes), in Karachi - District South. It should be noted that Karachi-South is one of the 5 districts of Karachi. The number of female cancer cases have increased. The male/female ratio in the Karachi Cancer Registry is M F = 1: 1 .04 whereas the JPMC registry data showed a ratio of M : F = 1.4 1. Breast cancer remains the most common malignancy amongst the females, and the number of cases have shown an increase over the last decade. CR=33.3% of the total and JPMC=21.7% of the total]. The age distribution remains similar. Cancer of the lung has replaced pharyngeal carcinoma as the number one malignancy in the males. Cancers of the ovary have shown a sharp increase. CR = 6.6% of the total and JPMC = 4.5% of the total]. There is a sharp decline in the cancers of the pharynx in the females as well as in the males. [Females - KCR=2.2% of the total and JPMC=8.4%. Males - KCR=6.6% of the tatal and JPMC=17.0%]. Malignancies of the brain have become apparent in the list of the ten most common tumours. Malignancies of the bone have declined.

A recent institutional study of a similar nature from Peshawar cites skin and lymph nodes as the commonest site in males and breast in females³. The difference in the pattern is a probable indicator of tobacco abuse and environmental pollution in Karachi.

Incidence data from neighbouring countries is better organised (Table 3). The Madras Metropolitan Tumour Registry (MMTR) ⁴, covering a population of 3.8 million, showed an average annual worldstandardised age-adjusted rates (AAR) per 100,000 as 104.2 in males and 129.0 in females. Stomach (AAR:15.2) was the leading site of malignancy among males, followed by cancers of the lung (AAR:9.8) and oral cavity (AAR:9.4). Among females, cancer of the cervix (AAR:44.0) was the commonest cancer, followed by breast (AAR:2L7) and oral cavity cancers (AAR:9.8). The populationbased cancer registry, in Shanghai, covering a total population of about 5.7 million showed an annual average age-adjusted cancer incidence rates for all sites in males 246.9 and 169.1 for females⁵. The population-based cancer registry of Songkhla, southern region of Thailand, population of 1.2 million showed that the age-standardized rate for all cancers was 116.7 in males and 88.7 in females. Lung, oral cavity, liver, and esophagus were the main leading sites in males while the cervix and breast were outstanding in females⁶. In Japan the leading cancer site was stomach for males and females followed by lung, liver, colon and rectum in males and breast, colon and uterus in the females⁷. In Seoul the age standardized incidence rates were 232.4 per 100,000 in males and 147.9 per 100,000 in females. The major cancer sites were stomach, liver and lung in males and cervix, stomach and breast in females⁸. In Europe, the Murcia Cancer Registiv, south- east Spain (955,487 inhabitants), showed the crude (allages) annual incidence rates per 100,000 as 238 in males and 179 in females. Lung and larynx were the most common malignancies amongst the males, whilst cancer breast was the most common cancer among women with an age-standardized rate of 29.4 per 1 00,000⁹. In Netherlands, the incidence rates for all malignancies were 443 per 100,000 males and 309 per 100,000 females. The most common cancers were lung cancer in males and breast cancer in females, accounting for 24% and 31% of the total cancer incidence by sex, respectively 10.

The incidence of cancer appears to be slightly lower in Karachi as compared to developed countries, but is at par with neighbouring countries. The low incidence may also be an indicator of undercoverage, as it often happens with new registries. The pattern of malignancies as far as the most common cancers go, is similar however to the western countries, with lung and breast being the commonest tumors amongst the males and females respectively. The Asian countries have stom ach/Iung/oralcavity/l i ver as the commonest tumors amongst the males and cervix/breast amongst the females. Pakistan being a Muslim country the incidence of cervical cancer showed an expected low figure.

Acknowledgements

The authors acknowledge: (1). Technical help given to the Karachi Cancer Registry by the International Agency for Research on Cancer; (2). Dr. D.M. Parkin, Chief, Unit of Descriptive Epidemiology and Dr. Sankaranarayanan from the Unit of Descriptive Epidemiology, IARC, for their technical support; (3). Prof. N.A. Jafarey, Vice Chancellor, Ziauddin Medical University Hospital and Prof. S.M.H. Zaidi, Director, Baqai Institute of Oncology for their support; (4). Prof. M. Khurshid and the staff of the Pathology Department Aga Khan University Hospital, Karachi and (5) Government of Sindh.

References

- 1. Population Census of Pakistan, 1981. Population Census Organisation, Islamabad, Statistical Division. Government of Pakistan 1982.
- 2. Parkm DM, Cancer Occurrence in Developing Countries. (IARC Scientific Publication No. 75), Lyon, International Agency for Research on Cancer, 1986. pp 259-65.
- 3. Khan SM, Gillani J, Nasreen S. et al. Cancer in north-west Pakistan and Afghan refugees. J. Pak. Med. Assoc. 1997;47:122-24.
- 4. Shanta V. Gajalakshrni CK, Swaminathan R, et al Cancer registration in Madras Metropolitan Tumor Registry. India. Etir. J. Cancer, 994:30:974-78.
- 5. Gao YF. Cancer incidence in Shanghai during 1973-77. Natl. Cancer Inst. Monogr., 1 982;62:43-46.
- 6. Thongsuksai P, Sriplung H, Phungrassami 1. et al. Cancer incidence in Songkhla. southern Thailand, 1990-1994. Southeast Asian J. Trop. Med. Public Health; 1997;3:1-10.
- 7. Cancer Incidence in Japan, 1985-89: re-estimation based on data from population-based cancer registries. The research group for population-based cancer registration in Japan. Jpn. J. Clin. Oncol; 1998;28:54-67.
- 8. Kim JP, Park IS, Ahu YO. et al. 1991 Cancer incidence in Seoul, KQrea: results of the implementation study of the Seoul Cancer Registry .I.Korean Med. Sci. 1995 10:74-84.
- 9. Navarro C, Perez-Flores D, Coleman MP. Cancer incidence in Mureia, Spain, in 1982: first results from a population-based cancer registry. hit. J. Cancer 1986;1 5;38: 1-7.
- 10. Work group annual report Netherlands Cancer Registration, Initial results of the Netherlands Cancer Registration, Ned. Tijdschr Geneeskd, 1992;5;136:2418-21.